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Project #1: Long-lived Tfh cells 
 
 The CD4 memory compartment has been subdivided into 3 distinct subsets that have 
different functions: inflammatory T effector memory (Tem), T central memory (Tcm), and 
tissue resident memory (Trm) cells. Whether T follicular helper (Tfh) cells that orchestrate the 
humoral response persist after the pathogen is cleared is controversial. We were able to show 
that Tfh cells are long-lived but extremely susceptible to NAD induced cell death (NICD) and 
therefore have previously been overlooked. Further characterization of Tfh cells revealed that 
folate receptor 4 (FR4) is a superior marker to CXCR5 in identifying Tfh memory cells. 
Surprisingly, Tfh memory cells maintain an anabolic state characterized by increased glucose 
uptake and mTORc1 activity yet retain full developmental plasticity. Furthermore, we identified 
a previously unknown functional role of Tfh memory cells in contributing to the maintenance 
of the humoral immune response beyond effector time points. 
 
Project #2: GP61 variants 
 
 Upon a viral infection, naïve CD4 T cells differentiate into inflammatory T helper 1 (Th1) 
cells and Tfh cells which shape the antibody response. The role of the T cell receptor (TCR) 
signal strength on Th1 vs Tfh cell differentiation in a viral infection model is incompletely 
understood. Here, we developed a new tool that allows us to address this question in both 
acute and chronic viral infections. We generated LCMV strains with point mutations in the 
GP61 epitope, which is part of the LCMV glycoprotein and is recognized by TCR transgenic 
SMARTA cells. In acute infections, TCR signal strength positively correlated with Th1 
induction. In contrast, chronic infections preferentially induced Tfh cells with increasing TCR 
signal strength and led to acquisition of surface markers associated with chronic T cell 
stimulation. Thus, depending on the immune context, TCR signals exerts opposite effects on 
the Th1 versus Tfh generation.  
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1. GENERAL INTRODUCTION 
 
 
1.1. The adaptive immune system 
 
 
The adaptive immune system is triggered by vaccines or by pathogens that are able 
to evade the innate immune system, the body’s first cellular line of defense. In contrast to the 
innate immune response, which relies on the recognition of broadly conserved pathogen-
associated molecular patterns (PAMPs) through pattern recognition receptors (PRRs), 
adaptive immunity is highly specific to the invading pathogen and provides a tailored response 
to the threat. Adaptive immunity usually provides long-lasting protection by forming 
immunological memory that allows the body to “remember” the pathogen, and is therefore 
also referred to as acquired immunity. The presence of immunological memory leads to 
accelerated detection of a subsequent infection by the same pathogen and immediately 
triggers an enhanced response that leads to more efficient clearance of the pathogen (1). 
Immunological memory also forms the foundation of vaccination, one of the most-successful 
interventions created by human mankind in the fight and control of infectious diseases to 
reduce death and morbidity (2-4). The first well-documented successful vaccination was 
performed in 1796, when Edward Jenner inoculated a 8-year-old boy called James with 
pustule from milk-maids infected with cowpox to protect against smallpox infections (5). In 
1977, smallpox was officially eradicated (5). In the coming year, vaccines not only led to the 
eradication of smallpox, but also to the elimination of measles, poliomyelitis, rubella, and 
mumps from most parts of the world (6, 7). However, despite the enormous success of 
vaccines, there are numerous deadly infections for which there is no vaccine, e.g. HIV, malaria 
and tuberculosis (8). Historically, vaccines have been developed by a trial and error approach. 
To generate efficient vaccines against the above-mentioned diseases, we need to improve 
our understanding of the adaptive immunity in order to come up with novel and more 
systematic approaches (9-11). 
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The adaptive immune system consists of two major arms: the cell-mediated response 
is characterized by the killing of pathogen-infected host cells through activation of cytotoxic 
CD8 T cells and innate phagocytic cells. The humoral response impairs the spread of the 
infection in the extracellular compartment by inhibiting pathogen cell-entry through antibodies, 
which are pathogen-specific immunoglobulins secreted by B cells. Adaptive immune 
responses are initiated by a specialized subset of cells termed “antigen presenting cells” 
(APC). APCs consist of dendritic cells, macrophages and B cells, and their purpose is to 
degrade engulfed pathogens into small epitope peptides and present these on major 
histocompatibility complex (MHC) proteins to T cells (12). Subsequently, CD4 T helper cells 
differentiate into distinct effector subsets, thereby regulating the extent of both the cell-
mediated and humoral responses. 
In a viral infection, the adaptive immune response is regulated through early bifurcation 
of naïve CD4 T helper cells into Th1 and T follicular helper (Tfh) effector subsets. Th1 cells 
potentiate cell-mediated CD8 and macrophage cytotoxicity, while Tfh provide survival and 
proliferation signals to antibody producing B cells (13). Once an infection is cleared, most T 
and B effector cells die. However, the rest are long-lived and represent the immunological 
memory that facilitates the enhanced secondary response to subsequent infections (1).  
 
1.2. CD4 T cell differentiation 
 
It is well established that three signals are needed to activate naïve CD4 T cells, and 
the integration of these signals leads to extensive clonal expansion and differentiation into 
functionally distinct effector subsets (14). These three signals are composed of the signals 
received through the T cell receptor (TCR), the co-stimulatory receptors, and cytokine 
receptors.  
Naïve CD4 T cells migrate between secondary lymphoid organs (SLO) and the blood 
system via the lymph(15, 16). Upon activation through cognate antigen in periarteriolar 
lymphoid sheaths (PALS) of secondary lymphoid organs (SLO), naïve CD4 T cells stop 
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migrating and enter a clonal expansion phase, during which one single naïve T cell can give 
rise to more than 1000 daughter cells (17). To meet the bioenergetic needs during the 
proliferation phase, CD4 T cells have to generate not only enough ATP but also the metabolic 
intermediates needed to produce biomass. Thus, proliferating T cells change their metabolic 
programming towards glycolysis and production of proteins, lipids, and nucleic acids (18-21). 
Simultaneously, depending on the environmental cues they are exposed to, T cells 
differentiate into specialized subsets by undergoing distinct transcriptional programming 
regulated by subset-specific master transcription factors. Classically, 5 distinct CD4 effector 
subsets have been described, each requiring different cues and generating specific cytokines 
that have different functions (Figure 1). Th1 cells have been shown to be important in the 
control of intracellular bacteria and viruses and produce interferon-γ (IFN-γ). Th2 cells fight 
helminth and parasite infection by secreting interleukin-4 (IL-4), and Th17 generate IL-17 to 
combat fungal and extracellular bacterial pathogens (22). In contrast, Tfh cells are generated 
regardless of the encountered pathogen and mainly secrete IL-21. Lastly, immunosuppressive 
regulatory T cells (Tregs) secrete IL-10 and are important for the maintenance of self-tolerance 
by dampening the immune response and inflammation (22). While secretion of cytokines is 
only one of several ways helper T cells elicit their effector functions, they are helpful for 




Figure 1: CD4 T cell heterogeneity. Upon receiving the 3 signals needed for full activation, naïve CD4 T cells can 
extensively proliferate and simultaneously differentiate into distinct effector subsets. Each effector subset needs 
different cytokine stimulation, expresses a different master transcription factor, secretes its hallmark cytokine, and 
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T cell receptor signal 
 
The TCR signal is the most specific signal received by the T cell and the TCR defines 
its antigen-specificity. Each αβ T cell bears a unique heterodimeric TCR which was generated 
through the rearrangement of the DNA segments V, D and J for the β-chain and V and J for 
the α-chain during thymic development (23). CD4 T cells use their TCR to survey for antigen 
in the form of short peptides bound to major histocompatibility complex class II molecules 
(pMHC). pMHC is displayed on the surface of antigen presenting cells (APC) including 
dendritic cells (DC), B cells and macrophages (12). The TCR can interact with foreign and 
self-peptides presented by MHCII at a broad range of intensities (24-26). In fact, weak 
interactions with self-antigens are required for positive selection during T cell development in 
the thymus, and peripheral T cells also rely on interactions with endogenous pMHC to receive 
survival signals (27-31). Interactions with self pMHC are typically only 10-fold weaker than 
with non-self pMHC, but this small yet crucial difference can be accurately sensed by the 
highly evolved TCR signaling apparatus (32, 33). 
 Upon binding of antigen through the TCR α/β chains, TCR signal transduction is 
mediated by the T cell co-receptor protein complex CD3 consisting of a CD3 γ-chain, a δ-
chain, two ε-chains and two z-chains. Each chain contains at least one immunoreceptor 
tyrosine-based activation motif (ITAM) that gets phosphorylated by the CD4-bound tyrosine 
kinase Lck through the activation of the phosphatase CD45 (34-36). Subsequently, 
phosphorylated ITAMs recruit ZAP70 kinases via the Src homology 2 (SH2) binding domain 
to the TCR thereby triggering several intracellular signal transduction pathways (37). ZAP70 
phosphorylates linker for activation of T cells (LAT) which leads to the recruitment of more 
adaptor proteins, an increase in intracellular calcium and subsequently to the activation of 
calcineurin, protein kinase C (PKC) and the mitogen-activated protein (MAP) kinases (38). 
This ultimately leads to the activation of three important transcription factors: nuclear factor of 
activated T cells (NFAT), nuclear factor-κB (NF-κB), and activator protein 1 (AP-1), which in 
cooperation with co-stimulation and cytokine receptor signals lead to the full activation and 
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differentiation of T cells. Stronger TCR signal induces a stronger response and increased 
activity of the 3 transcription factors (39-41). Factors that influence TCR signal strength are 
the potency of the TCR/pMHC interaction (off rate), the duration of T cell-APC contacts (dwell 
time) and density of pMHC (affected by antigen dose and affinity of peptide for MHC) (42-44).   
Although co-stimulation and cytokines can also impact CD4 T cell differentiation, TCR 
signal strength seems to play a major role in early CD4 T cell fate determination (39, 41, 45-
55). This was shown in an elegant study by Tubo, et. al. where the early bifurcation of Th1 
and Tfh cells in monoclonal vs polyclonal settings was assessed (54). While TCR-transgenic 
monoclonal CD4 T cells underwent a reproducible differentiation pattern following Listeria 
monocytogenes infection, the polyclonal endogenous compartment showed a more 
variable/heterogenous differentiation. In both settings, the environmental factors were similar, 
highlighting that the microenvironment by itself is not sufficient to dictate CD4 T cell 
differentiation bias towards Th1 or Tfh cells. Despite being more physiologically relevant, the 
impact of TCR signal strength on polyclonal populations is not well understood due to technical 
limitations. The detection of antigen-specific polyclonal CD4 T cells relies on the use of 
tetramers, a reagent consisting of 4 recombinant pMHC molecules conjugated to a 
fluorophore. While tetramers are an invaluable tool for the field, only T cells bearing a high 
affinity TCR to the tetramer are able to bind them, leaving low affinity CD4 T cells undetectable 
(56). However, it was shown that low affinity T cells can make up a big part of the antigen-
specific CD4 pool when using Nur77 expression as a readout for TCR engagement in the 
tetramer negative fraction (56). Therefore, to enable the study of T cells expressing a low 
affinity TCR, the field has mainly relied on the adoptive transfer of cells from naïve TCR 
transgenic mice. While earlier studies suggested that high affinity T cell preferentially give rise 
to Tfh cells, growing evidence supports the idea that weak TCR signal can also generate Tfh 
cells (39, 41, 47, 48, 50, 51). Notably, these contradictory results might be a result of the 
infection or immunization model used. A recent study performed in humans further highlighted 
the importance of the TCR in CD4 T cell fate determination. By performing TCR sequencing 
in combination with peptide recognition, the authors were able to show that Tfh cells in tonsils 
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Figure 2: TCR signaling: Binding of the antigen by TCR α/β chains induces phosphorylation of Lck by CD45. This 
in turn leads to phosphorylation of the ITAM motifs of the CD3 complex and leads to the recruitment of ZAP70. 
Subsequently ZAP70 phosphorylates LAT and thereby triggers 3 intracellular pathways: The MAP kinase pathway 
leading to AP-1 activation, PKC pathway with NF-κB activation and calcineurin pathway with NFAT translocation 




 While TCR engagement is crucial for activation, it became apparent in the field that 
TCR signaling alone is not sufficient for complete activation of T cells, as cytotoxic T 
lymphocytes (CTL) are incapable of inducing an immune response to alloantigens (58, 59). In 
fact, it was later found that stimulation of the TCR alone results in T cell anergy, a state that 
renders T cells unresponsive (60). This led to the corroboration of an old hypothesis that a 
second signal is necessary to overcome anergy induction (61). Soon thereafter, the surface 
protein CD28 was identified as the molecule delivering the co-stimulatory signal required for 
full T cell activation after engagement of the ligand B7-1 (also known as CD80) expressed on 
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B cells (62-64). Later, an additional ligand for CD28 termed B7-2 (also known as CD86) was 
identified (65-67). CD28 is constitutively expressed on T cells, and signaling leads to the 
activation of AP-1 and NF-κB (68-71). Mechanistically, binding of CD28 ligands by the 
extracellular CD28 domain leads to the recruitment of intracellular binding proteins with SH 2 
and 3 domains to one of the intracellular YMNM motif of CD28, e.g. phosphatidylinositol 3-
kinase (PI3K) (72-74). PI3 kinases are heterodimeric kinases and in lymphocytes PI3Kδ is the 
most abundantly expressed isoform which is composed of a p85 regulatory subunit and a 
p110δ catalytic subunit (75). The p85 regulatory subunit contains an SH2 domain that binds 
to the YMNM motif, thereby allowing localization of p110δ to the plasma membrane. Activation 
of p110δ leads to the phosphorylation of phosphatidylinositol to phosphatidylinositol (3,4)-
biphosphate (PIP2) and phosphatidylinositol (3,4,5)-triphosphate (PIP3), and these lipids in 
turn activate downstream pathways by the recruitment of proteins with a PH binding domain 
(76). One of these downstream pathways involves the activation of phosphoinositide-
dependent protein kinase 1 (PDK1) and the protein kinase B (AKT/PKB) that successively 
regulate multiple pathways involved in metabolism and survival like glycolysis, mammalian 
target of rapamycin (mTOR), glycogen synthase kinase 3 (GSK3), or activation of forkhead 
box O (FOXO) transcription factors among others but also the production of the cytokine IL-2 
(71, 77-81).  
 Coinhibitory receptors also exist to balance the activating capacity of costimulatory 
receptors. CTLA4, also belonging the CD28 family, binds to the same ligands as CD28 (82, 
83). However, it binds the ligands with a greater avidity and provides an inhibitory rather than 
a stimulatory signal (83).  It does so by inhibiting TCR- and CD28-mediated signal 
transduction, inhibition of IL-2 synthesis and cell cycle arrest (84). In contrast to CD28, CTLA4 
is not constitutively expressed but is rapidly upregulated upon T cell activation (85). 
 Inducible T cell costimulator (ICOS) is, as the name implies, another receptor for co-
stimulatory signal that is expressed upon activation through TCR/CD28 stimulation (86, 87). 
It’s ligand, ICOSL, is constitutively expressed on all professional APCs (86, 88, 89). ICOS, like 
CD28, induces PI3K activity but with an enhanced production of PIP3 resulting in a stronger 
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Akt phosphorylation than CD28 which is due to a mutation in the intracellular motif (YMFM for 
ICOS) (90, 91). ICOS and ICOS ligand deficient mice show a profound impairment of class-
switched antibodies concomitant with reduced number and size of GCs (92) . However, the 
disruption of the ICOS-PI3K pathway in T cells does not fully mirror the ICOS knockout 
phenotype suggesting that ICOS activates other pathways in addition to PI3K (93, 94). Indeed, 
an additional intracellular signaling motif named IProx was found in the intracellular domain of 
ICOS which is absent CD28 (95). IProx recruits TBK1 which was shown to play a crucial role 





Cytokines provide signal 3 to naïve CD4 T cells to fine-tune the adaptive immune 
response by inducing different types of immune responses that eliminate specific types of 
pathogens. The type of the immune response elicited might be influenced by the type of innate 
lymphoid cells (ILCs) activated early in the response (96). Type 1 responses induce the 
activation of ILC1s, which produce IFN-γ, and the secretion of IL-12 by dendritic cells and 
macrophages. These cytokines generate an environment that promotes the differentiation of 
naïve CD4 T-cells to Th1 cells to fight intracellular bacterial infections or viruses (97, 98). 
Following stimulation of IL-12 and IFN-γ, signaling transducer and activator of transcription 
(STAT) family protein members 4 respectively 1 are activated and Tbet, the lineage-defining 
transcription factor of Th1, is induced (97-99). Tbet, like other master transcription factors, 
induces lineage-specific genes while simultaneously repressing genes promoting alternate 
lineages, thereby stabilizing the Th1 cell fate (100, 101). Helminth and parasite infections lead 
to ILC2 activation and consequently to the secretion of IL-4 facilitating the generation of Th2 
cells (102). IL-4 induces the activation of STAT6 and the expression of the Th2 master 
transcription factor GATA-3 (103-107). Type 3 responses are directed against fungi or 
extracellular bacteria and are characterized by the induction of Th17 cells and the activity of 
STAT3 through IL-6/IL-23 to induce ROR-γt expression (108, 109). Interestingly, Tfh cells 
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which are induced in all types of immune responses, share the dependency of STAT3 
signaling with Th17 cells, yet require stimulation of Il-21 through IL-21 receptor and rely on the 
lineage defining transcription factor Bcl6 (110-116). Lastly, Treg cells rely on the IL-2-STAT5 




1.3. CD4 T cell response to viral infections 
 
 
The CD4 T cell response to viral infections can be divided into 3 phases: expansion, 
contraction, and memory. Activation of naïve CD4 T cells leads to clonal burst and 
differentiation into the effector subsets Th1 and Tfh that help the immune system clear the 
virus. Once the late effector stage is reached (end of expansion phase) and the infection is 
cleared, Th1 and Tfh cells undergo clonal contraction leaving behind a small population of 
long-lived memory cells that exhibit improved functions upon reactivation (121). In contrast, 
chronic infections with persisting antigen lead to a state of T cell dysfunction termed 
exhaustion, which may serve to limit immunopathology. 
Th1 and Tfh cells stimulate the two different arms of the adaptive immune system, namely 
the cell-mediated and the humoral arm respectively. The two subsets provide help via 
distinct mechanisms and also differ strongly in their differentiation programs and migration 
patterns. How and when the bifurcation of Th1 and Tfh cell differentiation occurs is still not 
fully resolved. Previous reports showed that some CD4 T cells early after infection co-
express both Bcl6 and Tbet at high levels, which is somewhat counterintuitive due to their 
opposite effects on gene transcription (122-124). One possibility is that Bcl6/Tbet co-
expressing cells may become Th1 cells after Bcl6 downregulation (124). On the other hand, 
a recent study using Tbet fate reporter mice found that a subset of Tfh cells in germinal 
centers previously expressed Tbet and to a certain degree retains Th1 helper capacity (125). 
Therefore, Th1 and Tfh cells early during the expansion phase most likely undergo a 
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transitional stage during differentiation with shared characteristics before committing to one 
lineage.  
 
T helper 1 cells 
 
Following immunization, CD4 T cells induce a potent CD8 response that helps to 
control infections. The ability of CD4 to help CD8 T cells is mainly attributed Th1 cells in a viral 
infection model. As already described above, naïve CD4 T cells differentiate into Th1 cells 
upon interaction with dendritic cells in the presence of IL-12 and IFN-γ leading to the up-
regulation of STAT 1 and 4 and concomitant expression of Tbet, the master transcriptional 
regulator of Th1 cells (97-99). Tbet further induces IFN-γ production which leads to the 
expression of IL-12 receptor allowing specific expansion of Th1 cells (98) while repressing 
alternate cell fates like Th2/Th17 through gene expression inhibition (126-128). Besides Tbet, 
the Runt-related transcription factors Runx1 and Runx3 play an important role in the Th1 
differentiation process. Both Runx transcription factors can repress GATA3 activity, either 
through repression of gene transcription or through direct protein interaction (129, 130).  
Once the Th1-fate is stabilized, Th1 effectors help shape the CD8 response in several 
ways, stimulating CD8s either directly or indirectly (131). As an example of indirect stimulation 
of CD8 responses, Th1 cells can “license” dendritic cells to increase antigen-presentation and 
expression of co-stimulatory ligands, therefore potentiating DCs to stimulate CD8 T cells (132, 
133). Furthermore, DC licensing induces the secretion of the chemokines CCL3 and CCL4 
which attracts naïve CD8 T, providing an explanation for how a rare CD8 population can 
efficiently be activated (134). Th1 cells license DCs via CD40-stimulation through CD40L 
expression (135-137). However, CD40:CD40L interactions can also occur between Th1 cells 
and CD8 T cells directly although this seems to be more important for the generation of a long-
lived memory compartment than for potentiating primary responses (138). The secretion of 
cytokines by Th1 cells is an example of direct stimulation of the cytotoxic T cell response. CD4 
T cells have been shown to be a major source of IL-2, allowing expansion and enhanced 
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survival of CD8 T, but also increasing secondary responsiveness of CD8s (139-143). 
However, it is noteworthy that IL-2 concentrations can be modulated by the 
immunosuppressive CD4 Treg compartment. High consumption of IL-2 by Tregs can decrease 
the availability of IL-2 and thereby suppress CD8 T cell expansion, but it also improves the 
responsiveness of memory T cells to secondary infections through the inhibition of terminal 
differentiation (144-147). Th1 cells act not only on CD8 T cells but also activate and potentiate 
the cytotoxicity of macrophages. They achieve this by providing CD40L as well as stimulation 
through IFN-γ secretion, the two essential signals needed for macrophage activation (148-
151). Subsequently, macrophages take on antimicrobial effector cell function via ROS-
production and induce TNF-α secretion in macrophages (149, 150). 
Another important feature of Th1 cells is their migration pattern. Licensing of DCs in 
SLOs is important, but effector functions directly at the site of inflammation in the infected 
organs are crucial for the full potential of Th1 cells (152). Migration of Th1 cells from SLOs to 
infected peripheral organs is mediated in two ways. First, T cells lose the expression of CCR7 
and CD62L, which retain T-cells in the T cell zone of SLOs (153-155). Furthermore, 
upregulation of sphingosine 1-phosophate receptor (S1PR), P-selectin glycoprotein ligand-1 
(PSGL-1), and CXCR3 allows SLO egress, migration along blood vessels and tissue entry at 
the site of inflammation through endothelial cells (153-155). In summary, the distinct migration 
properties of Th1 cells allows this subset to not only act in SLOs but also to coordinate cell-
mediated killing in inflamed tissue, highlighting their systemic effect in orchestrating the 
cytotoxic response.  
 
 
T follicular helper cells 
 
In the year 2000, a new helper subset was identified that localizes in the B cell follicle 
where it promotes B cell responses, and was therefore termed T follicular helper cell (Tfh) 
(156, 157). At the time, it was unclear whether this newly identified subpopulation truly 
represented a distinct CD4 T cell lineage. This view changed with the identification of Bcl6 as 
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the master transcription factor for Tfh cells (114-116) and the discovery of distinct signals 
required for the differentiation of Tfh cells (110). Tfh differentiation from a naïve CD4 T cell is 
described as a multistage process involving interactions with both DCs and B cells, although 
this has recently been challenged by a study using a malaria infection model that implies that 
B cells alone are sufficient to prime Tfh cells (158-160). The classical Tfh differentiation 
process as currently understood is initiated by initial DC priming of naïve CD4 T cells resulting 
in early Tfh fate commitment (160-162). Expression of the chemokine receptor CXCR5 and 
Bcl6 through IL-6 stimulation allows migration of Tfh precursor cells from the T cell zone to the 
T-B border of B cell follicles (114, 160, 163, 164). Mechanistically, IL-6 stimulation induces 
Bcl6 expression which in turn represses CC chemokine receptor 7 (CCR7) and P-selectin 
glycoprotein 1 (PSGL-1) expression while simultaneously stabilizing CXCR5 expression (165-
168). Further antigenic and ICOS stimulation via B cells is essential for the maintenance of 
Tfh cell fate and their ultimate localization in the germinal centers (GC) (158, 162).  
Tfh cells play a crucial role in shaping the B cell response. Starting with the first 
interaction at the T-B border, Tfh cells instruct B cells to either differentiate into short-lived 
plasma cells (also referred to as extrafollicular plasma cells or GC-independent plasma cells), 
GC-independent memory B cells or GC B cells (169-172). These B cell subsets have distinct 
functions: extrafollicular plasma cells provide the first round of antibodies to limit the spread 
of the infection, GC-independent memory B cells might represent a stem-like reservoir for 
secondary GC reactions, and the GC B cells undergo class-switch and affinity maturation, 
ultimately generating a highly efficient and long-lasting humoral response (158, 173). Germinal 
centers are composed of two distinct zones in which GC B cells can circulate: the light zone 
(LZ) and the dark zone (DZ). GC B cells in the dark zone undergo a process called somatic 
hypermutation, in which activation-induced cytidine deaminase (AID) induces mutations in the 
B cell receptor (BCR) to alter the affinity of the BCR to the antigen that is present in the GC 
(174). Furthermore, the mutated B cells undergo clonal expansion before they migrate from 
the DZ to the LZ (175). In the LZ, GC B cells pick up antigen from FDCs and present it to Tfh 
cells via peptide:MHC complexes. The more antigen that is presented to the Tfh cell, the more 
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survival signals the GC B cell will get before returning to the DZ for the next round of affinity 
maturation. The number of additional cell divisions and mutations GC B cells undergo was 
found to directly correlate with the help provided by Tfh cells (176). Alternatively, GC B cells 
can exit the GC to differentiate into memory B cells or plasma cells, and this fate decision 
seems to be dependent on their affinity, although the mechanism of how the cell fate is decided 
is incompletely understood (169, 177-185). Germinal center B cells that do not receive the 
required stimulus from Tfh cells because of the expression of low-affinity BCRs are negatively 
selected and undergo apoptosis (173, 186). The Tfh cells thus select for high affinity B cells 
while restricting low-affinity B cells (175, 187). Additionally, Tfh cells were shown to regulate 
the size of GCs (93, 115, 188). Tfh were also found to be present in the DZ, however, their 
functional role remains to be elucidated (189).  
How do Tfh cells provide help to GC B cells? The signals consist of both cytokines (IL-
21, IL-4) and direct cell-to-cell interaction (CD40L, signaling lymphocytic activation molecule 
(SLAM)). However, the amount of Tfh help is not  determined solely by TCR engagement but 
also by distinct costimulatory and coinhibitory signals through the interaction with the GC B 
cell (158). The importance of the proper regulation of help delivered by Tfh cells is highlighted 
by the finding that excessive Tfh help impairs clonal selection and affinity maturation leading 
to lower affinity antibodies over time (175). One of these regulators is SLAM expressed on LZ 
GC B cells (190). SLAM engagement on Tfh cells was shown to be required for cytokine 
production, as SLAM-associated protein (SAP) deficient Tfh cells are defective in both IL-4 
and IL-21 production (191). SAP transduces the signal received through SLAM and has shown 
to be important for T cell B cell adhesion (192). SAP was also shown to play an important role 
in the establishment of long-term humoral immunity but not in early antibody responses (193). 
ICOS triggering was identified as another important factor for cytokine production by Tfh cells, 
since blocking ICOS-signaling abrogated IL-21 production (194). Both IL-4 and IL-21 are 
important for the survival of B cells, induction of B cell proliferation, induction of class switch 
recombination (CSR), and plasma cell differentiation(182, 195, 196). These functions can also 
be attributed to CD40L, which is probably the best characterized B cell helper signal (197-
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200). Additionally, CD40L plays a role in stabilizing T:B interactions. Most interactions 
between Tfh cells and GC B cells have been shown to be rather short (201, 202). However, 
these interactions might be elongated through CD40L expression on Tfh cells as it can 
transiently enhance SLAM expression and thereby provide a feedforward loop to enhance T:B 
entanglement (183). In contrast, programmed cell death 1 (PD1) signaling received by PD1-
ligand expressed on B cells dampens the TCR signal in Tfh cells and thereby limits help (203). 
This is important as Tfh cells are constantly exposed to TCR stimulation due to the continuous 
presence of antigen and therefore must remain sensitive to TCR signaling to distinguish small 
differences in number of pMHC molecules expressed on GC B cells and subsequently deliver 
the appropriate amount of help.  
Because of the crucial role Tfh cells play in the generation of efficient antibody 
responses, Tfh cells are important in control of pathogens. However, it is noteworthy that Tfh 
hyperactivation can lead to misdirected B cell differentiation or antibody maturation which can 
also have negative consequences for the host. Tfh cells have been implicated in a number of 






Figure 3: Germinal center response. Naïve CD4 T cells get activated by DCs in the T cell zone and pre-Tfh cells 
subsequently migrate to the T:B border. Pre-Tfh cells interact with activated B cells that recognized cognate 
antigen. Upon proliferation, B cells either become extrafollicular SLPCs, GC-independent memory B cells or 
migrate to the GC with Tfh cells and become GC B cells. In the DZ of the GC, GC B cells undergo SHM and clonal 
expansion before migrating to the LZ. In the LZ, upon antigen capture from FDC and cognate interaction with Tfh 
cells. After the affinity selection process in the LZ, GC B cells are either fated to die, become memory B cells or 
LLPCs, or undergo an additional round of affinity maturation. DZ: dark zone, FDC: follicular dendritic cell, GC: 
germinal center, LLPC: long lived plasma cell, LZ: light zone, SHM: somatic hypermutation, SLPC: short lived 
plasma cell. Adapted from Mesin et al. (204). 
 
T cell memory 
 Once pathogens are cleared from the host, effector CD4 T cells undergo clonal 
contraction, leaving most of the expanded cells fated to die (205). However, a few pathogen 
specific CD4 T cells survive and are long-lived, and are termed CD4 memory T cells. When 
and how memory CD4 T cells are generated needs to be further investigated. First, whether 
memory T cells arise from effectors late in the immune response, or whether memory 
precursor cells bifurcate early after activation from effector T cells is still under debate (160, 






























memory T cells would be achieved mechanistically. For example, memory cells could arise 
from asymmetric cell division (ACD), however since ACD is a rare event, it can likely not 
explain early bifurcation to full extent, but might contribute to it (213).  
 Memory T cells are classically defined to have the following characteristics: upon a 
subsequent infection of the same pathogen, these cells can be re-activated and reacquire 
effector functions quickly, proliferate earlier than primary activated T cells, and display higher 
extent of effector function which can be attributed to the increased precursor frequencies 
compared to their naïve counterparts (121).  However, most studies have focused on the CD8 
memory compartment, whereas the CD4 memory cells remain understudied. CD4 memory 
cells have classically been subdivided into T effector memory cells (Tem) and T central 
memory cells (Tcm) based on their expression of migratory markers CCR7 and CD62L (214). 
While Tem were shown to maintain limited expansion potential but acquire imminent effector 
function and are able to survey tissues (Th1 characteristics), Tcm cells are able to secrete IL-
2 and can proliferate extensively before acquiring effector functions and mainly circulate in 
lymph (214). More recently, a third memory population has been described that takes up 
permanent residency in organs and was subsequently called tissue resident memory T cell 
(Trm). Trm act as a first line of defense upon reinfection in tissues (215). In addition to these 
subsets, it was shown that memory CD4 cells can promote secondary B cell responses, 
suggesting that Tfh cells persist for a prolonged time even though previous studies failed to 
identify bona fide Tfh memory cells (163, 216-219) . The discrepancy might be explained with 
the fact that effector Tfh cells gradually lose their hallmark surface proteins including CXCR5 
and PD1 (163, 208, 216, 220, 221). Furthermore, Tfh cells have a substantial overlap with 
Tcm in regards to surface markers (CXCR5, ICOS) and transcription factors (TCF1, STAT3 
and ID3) making it difficult to clearly discriminate the two subsets (216, 222-226). The shared 
characteristics likely explains the different results obtained with respect to plasticity (the ability 
to adapt a new lineage, e.g. Tfh becoming a Th1 cell) of the distinct CD4 memory subsets 
upon re-activation. Recently, Thpok was identified as an important transcription factor for 
functional fitness of Tcm cells and a distinct memory precursor population expressing Thpok 
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was identified early after infection (207). The gene signature of Thpok expressing cells 
included the lymphoid homing marker Ccr7 and the survival factor Bcl2 among others. 
However, this gene signature was absent in Tfh effector cells, indicating an early bifurcation 
of Tcm precursor and Tfh memory cells. This idea is further supported by the fact that the TCR 
repertoire of Tfh cells in humans is distinct from non-Tfh cells (57). Whether these long-lived 
Tfh cells represent a bona fide memory population capable of self-renewal or whether they 
represent remnants from the effector response requires further investigation.  
 
T cell exhaustion 
 
In cases where the pathogen doesn’t get cleared from the host but persists and 
establishes a chronic infection, T cells can acquire yet another state called T cell exhaustion. 
This dysfunctional state is characterized by a) limited proliferation potential, b) limited cytokine 
secretion and c) expression of co-inhibitory receptors like PD-1, Lag3, Tim3, CTLA4 and 
others (227, 228). Although most studies on T cell exhaustion have focused on the CD8 
compartment, CD4 cells acquire similar characteristics in chronic infections (229-232). From 
an evolutionary point of view, T cell exhaustion most likely represents a safety program of the 
body to circumvent extensive immunopathology caused by excessive inflammation. For 
example, in an experimental setup that allows for the reactivation of a high number of 
inflammatory Th1 cells before the exhaustion program is acquired triggers lethal 
immunopathology (233).  
However, heterogeneous populations of exhausted T cells exist, and the 
developmental relationship of these distinct subsets have been identified (234). Terminally 
exhausted T cells exhibit an irreversible transcriptional and epigenetic state that cannot be 
reprogrammed to re-acquire effector functions (235). In contrast, chronic infections also lead 
to the emergence of a stem-like CD8 population expressing intermediate levels of PD-1, 
CXCR5, and other proteins associated with a Tfh phenotype (236, 237). Despite their dormant 
state, stem-like CD8 T cells can be re-invigorated by PD-1 blockade leading to proliferation 
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and increased effector functions representing a major advancement in the treatment of cancer 
and other chronic diseases (237-240). However, re-activated stem-like CD8 T cells retain their 
exhaustion phenotype on an epigenetic level upon PD-1 blockade therapy, and whether these 
cells can also be reprogrammed at the chromatin level remains unknown (241). How the T 
cell exhaustion program is induced remained an open question until TOX was identified as a 
master regulator (242-246). Interestingly, TOX expressing cells can be identified early after 
infection suggesting an early divergency of exhausted T cells from effector or memory T cells. 
Whether TOX plays a role in CD4 T cell exhaustion and whether the CD4 exhaustion 
compartment is as heterogenous as the CD8 counterpart has not been investigated yet.  
 
1.4. Viral infections 
 
 
Broadly speaking, viral infections can be classified into two major types: acutely 
resolved and persistent viruses. Persistent infections can be further classified into active 
versus latent persistent infections. The hallmark feature of latent chronic infections are the 
alternating states of active viral replication and quiescent non-replicating phases. Several 
factors like viral replicative capacity, tropism, immune evasion strategies and others 
determine whether the outcome of an infection is acute or persistent (247). 
Continuous productive replication is used by viruses like human immunodeficiency virus 
(HIV) and hepatitis B and C virus (HBV/HCV) in humans. In mice, lymphocytic 
choriomeningitis virus (LCMV) belongs in the former virus category, although different 
strains with different infection outcomes exist (248). The LCMV model has been widely used 
to study cell-mediated and humoral responses in acute and chronic settings, and several key 
concepts have been identified using LCMV (248). LCMV was also the infection model used 
in both projects described in this thesis.  
 
Lymphocytic Choriomeningitis virus 
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 LCMV belongs to the family of Arenaviruses and is a naturally occurring infection in 
mice. The virus is a non-cytopathic bi-segmented ambisense single-stranded RNA virus (249). 
The two segments of the viral genome each encode for two proteins. The L segment encodes 
for the RNA polymerase (L protein) and the matrix protein (Z protein) (249). The small S 
segment encodes for the nucleoprotein (NP) and the glycoprotein (GP) precursor which is 
cleaved into the extracellular subunit GP1 and the transmembrane subunit GP2 which then 
form the homotrimeric glycoprotein (250). The GP then facilitates infection of cells mainly 
through the interaction with the widely expressed glycoprotein α-dystroglycan (α-DG) (251). 
After binding, the virus particles are then taken up in smooth-walled vesicles and fused with 
acidified endosomes (252). The viral RNA then reaches the cytoplasm where the NP and L 
proteins induce viral replication followed by assembly and budding of virions mediated by the 
Z protein (253-255).  
LCMV was shown to infect macrophages, dendritic cells, fibroblasts, fibroblastic 
reticular cells, endothelial cells, and hepatocytes (256-260). However, several distinct LCMV 
strains exist and they exhibit differences in viral tropism and replicative capacity that can result 
in either acute or chronic infections (261). For example, LCMV Armstrong induces an acute 
infection, whereas Clone-13 leads to a persistent infection. Interestingly, the acute Armstrong 
strain and the chronic Clone-13 strain only differ in two amino acids with a functional impact 
(262). The first mutation in the glycoprotein increases affinity towards α-DG leading to an 
improved infectivity of dendritic cells (263). The second mutation in the polymerase increases 
the viral replicative capacity and was reported to be the primary determinant for viral 
persistence (262). Having two viral strains that are highly similar to each other yet generate 
different outcomes represents one of the major advantages of LCMV because it allows the 
comparison of acute and chronic viral infections side by side. Furthermore, due to the simple 
organization of the genome, LCMV rescue systems exist that allow the study of various 
mutations in the virus and its functional consequences for the host, making LCMV an ideal 
infection model to study immune responses (264).  
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2. AIM OF THE PROJECTS 
 
 
2.1. Project #1: Long-lived Tfh cells 
 
The existence of bona fide Tfh memory cells is controversial and is complicated by the 
down-regulation of hallmark Tfh proteins like CXCR5 and PD1 and the vast overlap of 
additional markers associated with both Tfh and Tcm subsets: ICOS, Bcl6, STAT3, TCF1, Id3 
etc. (208, 216, 223-226). Therefore, the aim of this project was to investigate whether Tfh cells 
are long-lived, how they can be discriminated from Tcm cells and to further characterize this 
compartment. Specifically, we wanted to address survival requirements of Tfh memory cells, 
investigate their potential to trans-differentiate into other subsets like Th1, and to assess their 
function. 
 
2.2. Project #2: GP61 variants 
 
Upon viral infection, naïve CD4 T cells receive signals through the TCR, co-stimulatory 
receptors and cytokines to differentiate into inflammatory Th1 cells and Tfh cells that support 
the generation of an efficient humoral response. How a naïve CD4 T cell decides to either 
become a Th1 or a Tfh cell is incompletely understood. However, several reports indicate that 
the TCR plays a crucial role (39, 41, 47, 48, 50, 51, 54, 55). Furthermore, how persistent 
antigen impacts CD4 differentiation hasn’t been addressed yet. Here we aimed to generate a 
new tool that allows us to investigate the impact of TCR signal strength on CD4 differentiation 
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Long-lived T follicular helper cells retain plasticity 
and help sustain humoral immunity
Marco Künzli1*, David Schreiner1*, Tamara C. Pereboom1, Nivedya Swarnalekha1,  
Ludivine C. Litzler1, Jonas Lötscher2, Yusuf I. Ertuna3, Julien Roux2,4, Florian Geier2,4,  
Roman P. Jakob5, Timm Maier5, Christoph Hess2,6, Justin J. Taylor7, Carolyn G. King1†
CD4+ memory T cells play an important role in protective immunity and are a key target in vaccine development. 
Many studies have focused on T central memory (Tcm) cells, whereas the existence and functional significance of 
long-lived T follicular helper (Tfh) cells are controversial. Here, we show that Tfh cells are highly susceptible to 
NAD-induced cell death (NICD) during isolation from tissues, leading to their underrepresentation in prior studies. 
NICD blockade reveals the persistence of abundant Tfh cells with high expression of hallmark Tfh markers to at least 
400 days after infection, by which time Tcm cells are no longer found. Using single-cell RNA-seq, we demonstrate 
that long-lived Tfh cells are transcriptionally distinct from Tcm cells, maintain stemness and self-renewal gene 
expression, and, in contrast to Tcm cells, are multipotent after recall. At the protein level, we show that folate 
receptor 4 (FR4) robustly discriminates long-lived Tfh cells from Tcm cells. Unexpectedly, long-lived Tfh cells con-
currently express a distinct glycolytic signature similar to trained immune cells, including elevated expression of 
mTOR-, HIF-1–, and cAMP-regulated genes. Late disruption of glycolysis/ICOS signaling leads to Tfh cell depletion 
concomitant with decreased splenic plasma cells and circulating antibody titers, demonstrating both unique 
homeostatic regulation of Tfh and their sustained function during the memory phase of the immune response. 
These results highlight the metabolic heterogeneity underlying distinct long-lived T cell subsets and establish Tfh 
cells as an attractive target for the induction of durable adaptive immunity.
INTRODUCTION
Vaccination and infection lead to the generation of protective immune 
responses mediated by memory T and B cells (1). Two major subsets 
of memory T cells have been described on the basis of differential 
expression of lymphoid homing receptors: CCR7+ central memory 
(Tcm) cells and CCR7! effector memory (Tem) cells (2). After chal-
lenge infection, Tcm cells produce interleukin-2 (IL-2) and maintain 
the capacity to proliferate and generate secondary effector cells. In 
contrast, Tem cells can immediately produce inflammatory cytokines 
but have more limited expansion. In addition to these subsets, CD4+ T 
follicular helper (Tfh) memory cells can promote secondary B cell 
expansion and class switching (3–7). The number of circulating Tfh 
cells correlates with the number of blood plasmablasts after vacci-
nation in humans and can be boosted to improve long-lived anti-
body production (8–10). These data suggest targeted generation of 
long-lived Tfh cells as a rational approach for improving vaccine 
design. However, despite the importance of Tfh cells for supporting 
antibody responses, the signals promoting maintenance and survival 
of these cells are not well understood. In addition, it is unclear whether 
Tfh cells retain the capacity to differentiate into diverse secondary 
effectors (3,"5,"6,"11). Analysis of long-lived Tfh cells is complicated 
by a gradual loss of phenotypic markers typically associated with Tfh 
effector cells, including programmed cell death protein 1 (PD1) and 
CXCR5, as well as the apparent decline of the CD4+ memory com-
partment compared with CD8+ memory cells over time (3,"6,"12–14). 
Moreover, the relationship between Tcm cells and Tfh effector cells, 
which share several surface markers and transcription factors includ-
ing CXCR5, inducible T-cell costimulator (ICOS), T cell factor 1 (TCF1), 
signal transducers and activators of transcription 3 (STAT3), and DNA- 
binding protein inhibitor ID-3 (ID3), is not well established (3,"15–19). 
Recently, a Tcm precursor signature, including markers for lymphoid 
homing (Ccr7) and survival (Bcl2), was identified among antigen- 
specific effector cells responding to viral infection (20). This signature, 
however, was not detected in Tfh effector cells, suggesting an early 
divergence between precursors of Tcm and long-lived Tfh. Nevertheless, 
it remains unclear whether Tfh cells found at later phases are remnants 
of a primary effector response or whether they represent a distinct 
population of self-renewing Tcm cells that share differentiation re-
quirements and phenotypic characteristics with Tfh cells.
Although informative, T cell receptor (TCR) transgenic models 
used to unravel these questions demonstrate intrinsically biased 
differentiation tendencies and may not reveal the full palette of CD4+ 
heterogeneity (21). In addition, many such studies require transfer-
ring high numbers of donor cells, which could affect T cell differen-
tiation (3,"22). Using tetramers to study the polyclonal T cell response, 
we determined that Tfh cells are particularly susceptible to nicotin-
amide adenine dinucleotide (NAD)–induced cell death (NICD) during 
isolation. By blocking NICD, we observed that Tfh cells persist in 
high numbers to at least 400 days after infection, whereas Tcm cells 
decline. Transcriptional and epigenetic profiling revealed that long-
lived Tfh cells constitutively engage glycolytic metabolism while 
remaining stem-like. Consistent with these findings, transfer exper-
iments revealed that long-lived Tfh cells, but not Tcm cells, can generate 
the full spectrum of secondary effectors. Although long-lived Tfh cells 
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can survive in the absence of antigen, they depend on sustained ICOS 
signals to preserve glycolytic and Tcf7-dependent gene expression. 
A reduction in Tfh cell numbers induced by late ICOS blockade led 
to a reduction in circulating antibody titers and splenic plasma cells, 
highlighting an underestimated contribution of long-lived Tfh cells 
to late phase humoral immune responses.
RESULTS
Tfh cells are susceptible to death during isolation
Tfh cells were recently described to express high levels of the puri-
nergic receptor P2X7 receptor (23,!24). P2X7R is an adenosine 5"- 
triphosphate–gated cation channel that can be adenosine 5"-diphosphate 
ribosylated by the cell surface enzyme ARTC2.2, rendering certain 
cell types, including regulatory T cells and resident memory T (Trm) 
cells, susceptible to NICD during isolation from the tissue (25,!26). 
Injection of an ARTC2.2-blocking nanobody (NICD protector) be-
fore organ harvest protects these subsets from NICD and improves 
their recovery from lymphoid organs (27,!28). To determine whether 
inhibition of ARTC2.2 could also improve the recovery of Tfh cells 
at effector and memory time points, we harvested antigen-specific 
T cells from NICD protector–treated mice after infection with lym-
phocytic choriomeningitis virus (LCMV). Polyclonal LCMV-specific 
CD4+ T cells were enriched using tetramer staining for IAb:nucleo protein 
(NP)309–328 (NP specific) or IAb:glycoprotein (GP)66–77 (GP66 specific) 
and analyzed for expression of Tfh-associated surface markers; a 
variety of gating strategies was used to place the results in the con-
text of previous studies assessing LCMV-induced Tfh cells (3,!12). In 
untreated mice, Tfh effector cells were clearly identified at day 15 
after infection but were largely absent by day 43 (Fig.!1A and fig. S1A). 
In contrast, treatment with NICD protector resulted in a signifi-
cant recovery of Tfh cells at all time points and with both T cell spec-
ificities, indicating a larger expansion and more prolonged survival 
of Tfh cells than previously appreciated (Fig.!1,!A!to!C). As the num-
ber of GP66-specific Tfh cells was about fourfold higher than 
NP- specific Tfh cells, we focused subsequent analyses on the GP66- 
specific T cell compartment (fig. S1B). Two-dimensional visual-
ization of the cytometry data by t-distributed stochastic neighbor 
embedding (tSNE) confirmed that NICD protector preferentially res-
cued cells with high expression of P2X7R (Fig.!1B). NICD protector 
also significantly improved the recovery of P-selectin glycoprotein 
ligand-1 (PSGL1)hiLy6Clo memory cells but had minimal impact 
on more terminally differentiated PSGL1hiLy6Chi (hereafter TH1) 
memory cells, in line with the levels of P2X7R expression on 
these subsets (Fig.!1,!C!and!D, and fig. S1C). In addition, NICD 
protector improved the recovery of Ly6clo and CXCR5+ cells 
after infection with Listeria monocytogenes, again correlating with 
P2X7R expression (fig. S1, D to G). After day >400, Tfh cells 
identified by all gating strategies persisted in LCMV- infected mice, 
whereas Ly6CloPSGL1hi memory cells, a heterogeneous population 
previously shown to contain a substantial proportion of Tcm, were 
nearly absent (Fig.!1, A!and!C, and fig. S1C) (12). These data suggest 
either a survival defect or conversion of Ly6CloPSGL1hi memory 
into one of the remaining memory cell subsets. Tfh cells isolated 
at late time points after infection were further phenotyped by flow 
cytometry and characterized by high expression of folate receptor 4 
(FR4), CD73, CXCR4, ICOS, and Bcl6 compared with TH1 and 
Ly6CloPSGL1hi memory cells (Fig.!1D). Although a similar pheno-
type was observed on polyclonal NP-specific Tfh cells isolated from 
LCMV-infected mice (fig. S1A), experiments using monoclonal T cells 
from NICD- protected SMARTA or NIP TCR transgenic strains 
generated substantially fewer long-lived Tfh cells (fig. S1H). These 
observations agree with previous reports showing a gradual de-
cline of Tfh-associated markers on transferred monoclonal populations 
and highlight the value of studying polyclonal responses, partic-
ularly given the tendency of different types of TCR transgenic 
T cells to undergo distinct and more limited patterns of differen-
tiation (3,!12,!21).
FR4 discriminates long-lived Tfh from transcriptionally 
distinct Tcm
To further investigate CD4+ T cell heterogeneity and regulation 
at memory time points, we performed single-cell RNA sequencing 
(scRNA-seq) on GP66-specific T cells isolated at day >35 after in-
fection. To assess the effect of NICD protector using a transcriptional 
readout, we sequenced cells from NICD protector–treated and un-
treated mice and found that treatment leads to an increase in pro-
portions of Tfh-like clusters (fig. S2A). To ensure consistency with 
other experiments, we performed further scRNA-seq analyses using 
the run with NICD protector. Principal components analysis (PCA) 
was used for dimension reduction, hierarchical clustering of the 
cells, and tSNE visualization (Fig.!2A and fig. S2B). Seven distinct 
clusters were enriched for genes associated with the following: Tfh 
cells (clusters 1 to 3, 37% of cells), Tcm cells (clusters 4 and 5, 45% of 
cells), and TH1 cells (clusters 6 and 7, 18% of cells) (Fig.!2,!A!and!B, 
and fig. S2B). The top defining genes in the Tfh clusters included 
established Tfh markers such as Izumo1r, Pdcd1, and Sh2d1a, as well 
as transcription factors expressed by CD4+ memory cells, including 
Klf6, Jun, and Junb (Fig.!2,!B!and!C) (23,!29). Tcm and TH1 clusters 
(4 to 7) exhibited higher expression of Il7r, S100a4, S100a6, Selplg, 
and various integrins (Fig.!2,!B!and!D), whereas clusters 6 and 7 were 
enriched for genes associated with TH1 differentiation including 
Cxcr6, Ccl5, Nkg7, and Id2 (Fig.!2,!B!and!E). Among TH1 clusters, 
cluster 7 represented the subset highest in Selplg, Ly6c2, and Il7r, 
whereas cluster 6 expressed higher levels of Cxcr6 and Id2 along with 
signatures of dysfunction and exhaustion (fig. S2, C to E) (20,!30). 
Cluster cell type identities were confirmed by scoring each cell for 
signature genes obtained from publicly available datasets and exam-
ining the scores across clusters (Fig.!2F and fig. S2F). Tfh and TH1 
signatures matched well with clusters 1 to 3 and 6 to 7, respectively, 
whereas clusters 4, 5, and 7 were enriched for the Tcm precursor 
signature reported by Ciucci et!al. (20) (Fig.!2F).
Within Tfh clusters 1 to 3, we observed stable expression of Izumo1r, 
which encodes FR4. Although the function of this receptor on T cells 
is not well understood, it has been shown to be expressed on Tfh 
effector and memory cells, as well as on anergic and regulatory 
CD4+ T cells (23,!31,!32). Compared with Cxcr5 and Pdcd1, Izumo1r 
served as a much cleaner transcriptional marker of the boundary 
between Tfh and non-Tfh cells (Fig.!2,!G!and!H). Unlike Izumo1r, 
Cxcr5 expression was also detected in non-Tfh clusters, although with 
a slight decrease from Tcm to TH1 (Fig.!2H). These findings were 
confirmed at the protein level, where CXCR5hi gating includes both 
FR4hi and FR4lo cells, whereas FR4hi gating largely excludes CXCR5lo 
cells (Fig.!2K). Unexpectedly, Ccr7 expression, highest in clusters 4 
and 5, was negatively correlated with Cxcr5 in cells from animals 
treated with NICD protector (in the bottom 4% of all genes), whereas 
cells from untreated animals showed a slight positive correlation (in 
the top 27% of all genes) (Fig.!2G). This trend was mainly driven by 
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the bona fide Tfh clusters (1 to 3) preferentially rescued from NICD, 
as illustrated by imputed expression levels of Cxcr5 versus Ccr7 
(Fig.!2I). A similar negative correlation was found between protein 
expression levels for CCR7 and CXCR5, with the highest CCR7- 
expressing cells falling within the Ly6CloPSGL1hi (hereafter Tcm) 
compartment (Fig.!2J and fig. S2G). Long-lived GP66-specific Tfh 
cells found in lymph nodes also expressed lower levels of CCR7 
compared with Tcm, consistent with the idea that Tfh cells generated 
in lymphoid organs are a noncirculating population similar to resident 
memory cells (fig. S2H) (33). Tfh cells have a higher expression of 
CD69 and enrichment for residency-associated genes (fig. S2, I and J) 
(34–36). Together, the use of FR4 as a marker for long-term Tfh identity 
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Fig. 1. Tfh cells are susceptible to death during isolation. (A) Flow cytometry analysis of GP66-specific CD4+ T cells isolated from the spleen at indicated time points 
after infection, with or without NICD protector using different gating strategies to identify long-lived Tfh cells (Ly6CloPSGL1lo, CXCR5hiPD1hi, or FR4hiLy6Clo). (B) tSNE plots 
of the GP66-specific CD4+ memory compartment with (middle and right) or without NICD protector (left) and overlaid P2X7R expression with red indicating the highest 
expression level (right). (C) Quantification of GP66-specific TH1 memory (red, Ly6ChiPSGL1hi) or long-lived Tfh cell (blue, Ly6CloPSGL1lo) numbers over time with (solid lines) 
or without (dashed lines) NICD protector gated as in Fig. 1D. Thin lines represent the means ± SD. (D) Representative flow cytometry plots and geometric mean fluores-
cence intensity (hereafter MFI) of the indicated marker in GP66-specific CD4+ memory cell subsets TH1 (red), Ly6CloPSGL1hi (green), and Tfh (blue) >40 days after infection. 
Data represent N = 2 independent experiments for (D) with n = 3 to 5 mice per group. Unpaired two-tailed Student’s t test was performed on each individual time point 
(C). *P < 0.05, **P < 0.01, ****P < 0.0001.
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Fig. 2. FR4 discriminates long-lived Tfh from transcriptionally distinct Tcm. (A) Unsupervised hierarchical clustering using Ward’s method: PCA and tSNE dimension 
reductions. (B) Heatmap showing scaled, centered single-cell expression of top 15 genes sorted according to cluster average log fold change (FC) , adjusted P value of 
<0.05. (C to E) Log-normalized expression of genes typical for Tfh (C), Tcm (D), and TH1 (E) populations. (F) Log-normalized average expression of published CD4+ signatures 
obtained by analysis of d7 effectors: Tfh, Tcm precursors, and TH1. (G) scRNA-seq: Rank of Ccr7 and Izumo1r (encoding FR4) among Spearman’s rank correlation coefficients 
between Cxcr5 and all other genes, NICD protector versus untreated. (H) Scaled, centered single-cell expression of Izumo1r in comparison with other common gating 
markers. (I) scRNA-seq: Cxcr5 versus Ccr7 on imputed data, colored by cluster. Dropout imputed using Seurat::AddImputedScore. (J and K) Flow cytometry analysis of 
CCR7, CXCR5, and FR4 on GP66-specific CD4+ memory subsets >50 days after infection gated as in Fig. 1D (J) or at the indicated time points after infection, with or without 
NICD protector (K). Data represent N = 2 independent experiments with n = 4 mice (J).
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improves upon previous gating strategies, which either allocate too 
many Tcm cells into a Tfh gate or depend upon markers like PD1, 
which is known to decline over time. We additionally noted that Hif1a, 
a transcription factor normally associated with glycolysis, was one 
of the top genes expressed by Tfh cells, consistent with the recently 
reported enrichment of this transcription factor in Tfh effectors and 
resident memory cells (Fig.!2B) (37–39). Together, these data high-
light clear transcriptional distinctions between Tcm cells and the ul-
timately more persistent NICD-rescued Tfh cells.
Long-lived Tfh cells are constitutively glycolytic
In addition to Hif1a expression, long-lived Tfh cells were enriched 
for mammalian target of rapamycin (mTOR)– and cyclic adenosine 
3",5"-monophosphate (cAMP)–regulated genes, suggesting a metabolic 
signature similar to that observed in trained immune cells (Fig.!3A 
and fig. S3, A to C) (40–44). Enhanced activation of mTOR-regulated 
genes was also observed in secondary analysis of microarray data on 
bulk sorted SMARTA Tfh memory cells (where PD1 protein expres-
sion was negative) and in recently published single-cell data from 
GP66-specific Tfh memory cells (fig. S3, D and E) and was further 
confirmed by quantitative polymerase chain reaction (qPCR) of 
mTOR- regulated genes in sorted CD4+ GP66-specific memory T cell 
populations (Fig.!3B) (3,!20,!43). These data indicate that long-lived 
Tfh cells may constitutively engage a glycolytic metabolism. To assess 
mTORC1 activity, we measured phosphorylation of TORC1 target 
ribosomal protein S6 (p-S6) directly after T cell isolation (Fig.!3C 
and fig. S3F). Both GP66-specific Tfh cells and CD44+ Tfh cells, which 
are phenotypically similar to antigen-specific Tfh cells (fig. S3G), ex-
hibited increased p-S6 compared with TH1 memory cells (Fig.!3C and 
fig. S3F). To exclude modulation of p-S6 due to tetramer-induced 
activation, we conducted experiments on ice with dasatinib, a 
tyrosine kinase inhibitor shown to temporarily block TCR-mediated 
signal transduction (45). Consistent with mTOR activation, long-
lived Tfh cells had increased uptake of the fluorescent glucose analog 
2-(N-(7-nitrobenz-2-oxa-1,3-diazol-4-yl)amino)-2-deoxyglucose) 
(2-NBDG) and an increased baseline extracellular acidification rate 
(ECAR) compared with TH1 memory cells (Fig.!3,!D!and!E). How-
ever, alongside this apparent increase in glycolytic metabolism, long- 
lived Tfh cells had slightly decreased expression of the amino acid 
transporter CD98 and the transcription factor c-myc (classically 
viewed as activation markers) compared with TH1 memory cells, 
indicating that not all measures of anabolic activity are increased 
(Fig.!3,!F!and!G).
To determine whether the shift toward glycolysis by long-lived 
Tfh cells was accompanied by a reduction in oxidative metabolism, 
we also assessed their baseline oxygen consumption rate (OCR). Al-
though we observed a slight reduction in basal respiration by long-
lived Tfh cells compared with TH1 memory cells, the maximum 
respiration and spare respiratory capacity were similar between these 
two populations (Fig.!3H). Transcriptionally, long-lived Tfh cells were 
also enriched for genes associated with oxidative phosphorylation 
and mitochondrial respiration, a signature associated with CD8+ 
memory T cell survival (fig. S3H). Because Tfh effectors were previ-
ously reported to have decreased mTOR activation and reduced 
glycolysis (46), we also assessed the metabolic capacity of cells isolated 
at day 10 after infection, reasoning that NICD protector might 
improve their survival and fitness. At this time point, Tfh effectors 
had slightly reduced basal ECAR compared with TH1 effectors but 
demonstrated normal glycolytic flux after the addition of carbonyl 
cyanide p- trifluoromethoxyphenylhydrazone (Fig.!3I). Similar to 
long-lived Tfh cells, Tfh effectors had equivalent baseline and maximal 
respiratory capacity to TH1 effectors, indicating that in contrast 
to an earlier report, Tfh cells isolated at earlier time points are also 
metabolically fit (Fig.!3J) (12). To test whether these discrepancies 
can be explained by the effect of NICD protector, we compared cell 
viability and 2-NBDG uptake with or without NICD protector from 
T cells isolated at days 10 (effector) and 110 (memory) after infec-
tion. NICD protector predominantly improved the viability of the 
Tfh subset as measured by annexin V staining (fig. S3, I and J). In ad-
dition, annexin V–negative Tfh cells from unprotected mice failed to 
take up 2-NBDG, demonstrating a fundamental metabolic difference 
from NICD- protected Tfh cells (fig. S3K). These results indicate that 
both Tfh effector and memory cells have greater metabolic capacity 
than previously appreciated.
To assess whether glycolysis/mTOR signaling are required to 
maintain long-lived Tfh cells, we examined Tfh cell survival in mice 
treated with the glycolysis inhibitor 2-deoxyglucose (2-DG) and 
rapamycin starting at day >40 after LCMV infection. After 2 weeks 
of 2-DG/rapamycin treatment, both the proportion and number of 
long-lived Tfh cells were significantly decreased, with the remaining 
Tfh cells showing reduced size consistent with less mTOR activation 
(Fig.!3,!K!and!L, and fig. S3L) (46). Signaling through P2X7R was 
recently suggested to restrain mTOR activation, leading to improved 
survival of CD8+ memory T cells (47). In contrast, P2X7R signals 
have been shown to restrain accumulation of Tfh effectors in Peyer’s 
patches (24). To assess whether P2X7R signals promote or restrain 
long-lived Tfh cell survival, we generated radiation bone marrow 
chimeras with a mixture of wild-type and P2X7R-deficient bone 
marrow. Sixty days after LCMV infection, P2X7R-deficient T cells 
generated an increased proportion of all memory cells, with the 
most significant increase in the Tfh compartment (Fig.!3,!M!and!N). 
These data demonstrate that P2X7R is a key negative regulator of 
long-lived Tfh cell accumulation and are consistent with a role for 
P2X7R in restraining mTOR activation.
Antigen is not required for the survival of long-lived Tfh cells
Glycolytic metabolism in T cells is often associated with activation 
and effector cell proliferation. To understand whether long-lived 
Tfh cells are responding to ongoing antigen stimulation, we exam-
ined Nur77 expression in LCMV-infected Nur77 reporter mice. 
About 30% of PSGL1loLy6Clo Tfh cells were Nur77 positive, with a 
slightly higher percentage in the CXCR5hiPD1hi Tfh compartment 
(Fig.!4A). Whereas PD1 expression was moderately increased on 
Nur77+ compared with Nur77# Tfh cells, it was much higher in both 
of these populations than in non-Tfh cells (Fig.!4B). Although these 
data indicate that a fraction of the long-lived Tfh compartment 
continues to respond to antigen, we did not observe a positive cor-
relation between PD1 expression and 2-NBDG uptake. Glucose 
uptake within the Tfh compartment is thus unlikely to be related 
to antigen stimulation (fig. S4A). Furthermore, increased 2-NBDG 
uptake was maintained by long-lived Tfh cells at >400 days of infection, 
by which time PD1 expression by Tfh cells has decreased (fig. S4B). 
To understand whether the glycolytic metabolism observed in long-
lived Tfh cells is related to proliferation, we administered bromo-2"- 
deoxyuridine (BrdU) in the drinking water of LCMV-infected mice 
beginning 40 days after infection. After 12 to 14 days, about 4 to 9% 
of Tfh cells incorporated BrdU, with a slightly higher proportion 
of CXCR5hiPD1hi Tfh cells staining positive (Fig.!4C). FR4-negative 
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Fig. 3. Long-lived Tfh cells are constitutively glycolytic. (A) Cumulative distribution of scaled, centered mRNA expression of Rptor-regulated genes by cluster (43). 
(B) qPCR of genes (arbitrary units relative to Rpl13a) in sort-purified GP66-specific TH1 memory (red), Tcm (green), and long-lived Tfh (blue) cells gated as in Fig. 1D. (C and 
D) Representative histograms and quantification of phospho-S6 Ser240/244 on long-lived CD44+ TH1 or Tfh cells compared with naïve CD4+ T cells (gray) (C) and 2-NBDG 
uptake (D) on GP66-specific cells >30 days after infection compared with unstained control (gray). (E) Basal ECAR and ECAR profile in response to Mito Stress test in TH1 
memory and long-lived Tfh cells pooled from 20 to 30 mice. (F and G) Histogram and MFI of CD98 (F) or c-myc GFP (G) in GP66-specific memory TH1 and long-lived Tfh. 
(H) Basal respiration and OCR profile in response to Mito Stress test on sorted CD44+ TH1 memory and long-lived Tfh. (I and J) ECAR profile (I) and OCR profile (J) in 
response to Mito Stress test in TH1 and Tfh effector cells (day 10 after infection) pooled from n = 12 to 14 mice. Representative flow cytometry plots (K) and quantification 
(L) of GP66-specific cells treated with vehicle or 2-DG/rapamycin. (M and N) P2X7R!/! to wild-type ratio of GP66-specific Tfh cells >60 days after infection (M) and analysis 
(N) using different gating strategies. Data are representative of N = 2 independent experiments depicting the means ± SD of n = 3 technical replicates (B) or 4 to 7 mice 
per group [(C) to (G) and (K) to (N)]. Dots represent cells from individual mice, and the line represents the mean. Unpaired (C, D, F, G, and L) or paired (M) two-tailed 
Student’s t test was performed with *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001.
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Tcm cells containing a mixture of CXCR5+ and CXCR5! cells showed 
a similar level of in"vivo cycling with about 3% of cells staining for 
BrdU, whereas 15% of TH1 memory cells stained positive, demon-
strating more extensive proliferation by this subset (Fig."4C). The 
glycolytic phenotype observed in long-lived Tfh cells is thus not 
strongly correlated with extensive cell division, although the slightly 
increased BrdU incorporation by CXCR5hiPD1hi Tfh cells may be 
related to ongoing antigen stimulation. To better understand the 
contribution of antigen to maintaining the long-lived Tfh compart-
ment, we transferred LCMV-specific effector cells isolated at day 10 
after infection into either LCMV infection matched or naïve recipients, 
followed by analysis of donor T cell phenotype. Thirty days after 
primary infection, TH1 memory cells were nearly absent in both 
transfer scenarios, indicating that TH1 effector cells survive poorly 
in this setting (Fig."4D). In contrast, GP66-specific Tfh cells were 
detected in both antigen-free (naïve) and infection-matched mice. 
Although fewer Tfh cells (with dampened expression of CXCR5 and 
PD1) were recovered from naïve mice, this may be partially due to 
ongoing expansion of Tfh effector cells in LCMV-infected recipients 
between days 10 and 15 after transfer (Figs."1C and 4, D and E). The 
PD1

























































































































































































































































































Fig. 4. Antigen is not re-
quired for the survival 
of long-lived Tfh cells. 
(A) Flow cytometry anal-
ysis of Nur77 expression 
by GP66-specific long-lived 
Tfh cells for the indicated 
gating strategies. (B) Rep-
resentative flow cytometry 
plots (left) and MFI (right) 
depicting PD1 expression 
on Nur77+ (blue dotted 
line) and Nur77! (tinted 
blue line) Tfh cells, gated 
as depicted in (A). (C) Flow 
cytometry plots (left) and 
quantification (right) of 
BrdU incorporation by 
GP66- specific CD4+ mem-
ory subsets after providing 
BrdU for 12 days in drink-
ing water. (D and E) To-
tal GP66-specific CD4+ 
T cells isolated at day 10 
after LCMV infection and 
transferred into congenic 
infection-matched (LCMV) 
or naïve mice. Donor cell 
phenotype analyzed at 
day 30 after infection. Rep-
resentative flow cytometry 
plots (D) and quantification 
(E) with gating for PSGL1lo 
Ly6Clo (left), PD1hiCXCR5hi 
(middle), and PSGL1loFR4hi 
(right). Dots represent cells 
from individual mice, and 
the line depicts the mean. 
Data represent N = 2 in-
dependent experiments 
with n = 4 to 5 mice. Paired 
(A) or unpaired two-tailed 
Student’s t test (B, C, and 
E) was performed with *P < 
0.05, **P < 0.01, ***P < 0.001.
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long-lived donor Tfh cells maintained high expression of FR4 with 
or without antigen, consistent with scRNA-seq data identifying 
Izumo1r/FR4 as a superior marker for long-lived Tfh cells (Figs.!2, 
C and H, and 4, D and E). Together, these data indicate that although 
Tfh cells with high expression of CXCR5 and PD1 survive optimally 
in the presence of antigen, they nevertheless persist in its absence 
and without classical signs of activation or proliferation.
Tfh cells generate multiple cell fates upon recall
Despite maintaining a glycolytic phenotype, long-lived Tfh cells are 
enriched for genes regulated by Tcf7 (encoding TCF1) and highly 
express Cd27, a marker associated with memory T cell survival, cyto-
kine production potential, and stemness (Fig.!5,!A!and!B) (48–50). 
Although higher expression of Tcf7!in long-lived Tfh cells matched 
higher expression of TCF1 protein, CD27 protein expression was 
substantially lower in Tfh compared with TH1 memory cells (Fig.!5, 
C!and!D). To determine whether the discrepancy between the CD27 
gene expression and protein expression was due to P2X7R-mediated 
shedding, we examined CD27 on memory cells isolated from LCMV- 
infected mixed bone marrow chimeras reconstituted with an equal 
mixture of P2X7R-deficient and wild-type bone marrow cells (51). 
We observed higher expression of CD27 on P2X7R-deficient long-
lived Tfh cells compared with both wild-type Tfh and TH1 memory 
cells (Fig.!5D). Consistent with high expression of both Tcf7 and 
Cd27, Tfh cells were also enriched for “early memory”–associated 
genes (fig. S5A) (52). In addition, construction of a cell develop-
mental trajectory indicated that Tfh and TH1 memory cells occupied 
opposite ends of a pseudotime trajectory, predicting enhanced dif-
ferentiation plasticity in one of these subsets (Fig.!5E and fig. S5, 
B and C) (53). To test this in!vivo, long-lived Tfh (FR4hiPSGL1loLy6Clo), 
TH1 memory (FR4loPSGL1hiLy6Chi), and Tcm (FR4loPSGL1hiLy6Clo) 
cells were sorted from LCMV-infected mice and transferred into naïve 
congenic recipients, followed by secondary challenge with LCMV 
(Fig.!5F). To prevent tetramer-induced activation, we stained cells 
for transfer in the presence of dasatinib. Twelve days after recall in-
fection, transferred Tfh cells differentiated into both Tfh and TH1 
effectors, demonstrating lineage flexibility (Fig.!5,!G!and!H). Con-
sistent with a stem-like character, transferred Tfh donor cells also 
expanded most upon reactivation, generating the largest pool of each 
secondary effector subset (Fig.!5I). In contrast, Tcm cells maintained 
the capacity to differentiate into both Ly6Chi and Ly6Clo effectors, 
but generated few Tfh effectors, suggesting more limited plasticity 
(Fig.!5,!G!to!I). Consistent with several reports, TH1 memory cells 
almost exclusively gave rise to Ly6Chi effectors, indicating more 
terminal differentiation of these cells (Fig.!5,!G!to!I) (3,!6). Together, 
these data demonstrate that despite engaging an anabolic metabolism 
often associated with effector cell proliferation and differentiation, 
long-lived Tfh cells have a stem-like, early memory signature and 
maintain the capacity to differentiate into multiple types of effectors 
after secondary challenge.
Epigenetic regulation of long-lived Tfh cells
To assess whether the distinct transcriptional signatures observed 
in Tfh and TH1 memory cells were also apparent at the epigenetic 
level, we compared chromatin accessibility of TH1 memory, long-
lived Tfh, and naïve T cells by assay for transposase-accessible chro-
matin using sequencing (ATAC-seq) (54). The majority of called 
peaks were shared among these three populations, with the highest 
number of unique peaks present in naïve CD4+ T cells (fig. S6A). 
PCA revealed that Tfh and TH1 memory cells are set apart from 
naïve T cells along PC1 yet separated from each other along PC2, 
indicating distinct accessibility profiles (Fig.!6A). Whereas TH1 
memory cells had more differentially open peaks annotated to 
exons, introns, and distal intergenic regions, long-lived Tfh cells had 
about 50% more differentially accessible peaks in promoter regions 
(fig. S6B). We thus focused on the significantly differentially acces-
sible promoter regions with a high fold change (log2 fold change > 1 
and false discovery rate!<!0.05) between at least two of the T cell 
subsets and performed hierarchical clustering. This resulted in clusters 
of genes with common accessibility patterns: e.g., up in naïve, up in 
memory, and up in naïve and long-lived Tfh (Fig.!6B and fig. S6C). 
For example, the Foxp1 promoter was exclusively accessible in naïve 
CD4+ T cells, consistent with its role as a gatekeeper of the naïve to 
memory T cell transition (55). Integrative analysis of ATAC-seq and 
RNA-seq data (in silico pseudo-bulk samples derived from scRNA-
seq data) revealed a correlation between the promoter accessibility 
and expression of genes defining Tfh and TH1 memory cell subsets 
(Fig.!6C) (3). Consistent with a study that assessed the DNA meth-
ylation status of various cytokine loci in Tfh and TH1 memory cells 
(3), we observed that the Gzmb promoter was exclusively accessible 
in TH1 memory cells, whereas the Ifny promoter was accessible in 
both populations, albeit at slightly lower levels in long-lived Tfh cells 
(Fig.!6D). In contrast to this earlier study, however, the promoter 
accessibility of the hallmark Tfh cytokine, Il21, was restricted to 
long-lived Tfh cells (Fig.!6D). In addition, one of the most accessible 
cytokine promoter regions in long-lived Tfh cells was the epidermal 
growth factor–like ligand amphiregulin (Areg), notable for its role in 
restoring tissue integrity after infection (56). To further assess dif-
ferences in the transcriptional regulation of Tfh and TH1 memory cells, 
we analyzed enriched binding motifs in called peaks using Hyper-
geometric Optimization of Motif EnRichment (HOMER) (57). In 
agreement with the scRNA-seq data, long-lived Tfh cells were en-
riched for motifs belonging to the TCF transcription factor family 
and activating protein 1 (AP1) family members, which are known 
to be similarly regulated in CD8+ memory cells (Fig.!6E) (58,!59). In 
contrast, TH1 memory peaks exhibited increased Runx and T-box 
transcription family member binding sites, consistent with the co-
operation of these transcription factors in regulating interferon-g and 
stabilizing TH1 fate in CD4+ T cells (Fig.!6F) (60,!61). These observa-
tions were further validated by applying single-cell regulatory network 
inference and clustering to the scRNA-seq data, which highlighted 
TCF/AP1 and Runx family members as regulators in long-lived Tfh 
and TH1 memory, respectively (fig. S6D). We next assessed functional 
pathways in the ATAC-seq data by running gene set enrichment 
analysis (GSEA) on differentially accessible promoter regions in long- 
lived Tfh compared with TH1 memory cells using both standard gene 
set categories and sets curated from relevant publications (fig. S6E). 
Here, we observed increased promoter accessibility in long-lived 
Tfh cells of Rptor- and Tcf7-regulated genes and genes activated in 
response to cAMP, suggesting that the anabolic and stem signatures 
of this population are strongly regulated at the epigenetic level 
(fig. S6E).Last, using Ingenuity Pathway Analysis (Qiagen, version 
01-14) to probe the functional regulation of long-lived Tfh cells, we 
identified ICOS-inducible T-cell costimulator ligand (ICOSL) sig-
naling as one of the top pathways enriched in both ATAC-seq and 
scRNA-seq datasets (fig. S6F) (62). These data raise the possibility that 
ICOS-mediated signals contribute to the maintenance and identity of 
long-lived Tfh via specific epigenetic modifications.
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Fig. 5. Tfh cells generate multiple cell fates upon recall. (A) Log-normalized average expression of genes tracking with Tcf7 (90). (B) scRNA-seq: Rank of Cd27 among 
Spearman’s rank correlation coefficients between Tcf7 and all other genes (left). Cd27 versus Tcf7 on imputed data (right), colored by cluster. (C and D) Flow cytometry 
analysis of TCF1 (C) in wild type and CD27 (D) in mixed wild-type and P2X7R!/! bone marrow chimera mice in TH1 (red), Tcm (green), and Tfh (blue) GP66-specific memory 
cells. (E) Density of cells in pseudotime using Monocle2 analysis. (F) GP66-specific TH1, Tcm, or Tfh CD4+ T cells sorted at days 35 to 45 after LCMV infection and transferred 
into congenic naïve mice. Recipient mice challenged with LCMV the following day. Donor cell phenotype analyzed at day 12 after infection. (G) Representative flow 
cytometry plots of TH1, Tcm, or Tfh donor cell phenotype. (H and I) Quantification of proportions (H) and numbers (I) of TH1 effectors (red), Tcm (green), and Tfh effectors 
(blue) from TH1, Tcm, or Tfh donors compared with endogenous response. Data represent N = 2 independent experiments with n = 5 (C) or 3 to 14 (D to H) mice per group 
with the thin line depicting the mean and the dots representing cells from individual mice. (I) Summarizes N = 2 independent experiments with n = 6 to 7 mice. One-way 
analysis of variance (ANOVA) followed by Tukey’s posttest for multiple comparisons (C) or unpaired two-tailed Student’s t test (D and I) with *P < 0.05 and ****P < 0.0001.
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ICOS signaling maintains Tfh cell identity at late time points
Although ICOS has an established role in primary Tfh responses, its 
role in maintaining CD4+ T cells in the long term is less clear. ICOS 
signaling has been shown to induce the expression of Tcf7!in Th17 
memory cells that maintain the plasticity to differentiate after 
stimulation (63). ICOS can also induce mTORC1 activation in both 
Tfh effector and T follicular regulatory effector cells, leading to further 
stabilization of the follicular T cell program (43,!64,!65). To test the 
hypothesis that ICOS signals contribute to the integration of stemness 
and anabolic metabolism in long-lived Tfh cells, we treated LCMV- 
infected mice with anti-ICOSL starting at day >50 after infection 
(Fig.!7A). After 12 days of treatment, the number of GP66-specific 
Tfh cells was decreased in anti-ICOSL–treated mice (Fig.!7B). Tfh cells 
remaining after ICOS blockade had decreased expression of TCF1 
and reduced activation of mTOR as measured by cell size (fig. S7, A 
and B). To further characterize the effects of anti-ICOSL blocking 
on long-lived Tfh cells, we performed RNA-seq at day 60 after infec-
tion on control and treated mice. Cells from mice treated with anti- 
ICOSL for 12 days before harvest exhibited lower transcription of 
key Tfh genes such as Pdcd1, Cxcr5, and Bcl6, whereas known TH1 
survival factors such as Bcl2 and Il7r were increased (Fig.!7C). GSEA 
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Fig. 6. Epigenetic regulation of long-lived Tfh cells. (A) PCA of ATAC-seq data on all peaks. (B) Heatmap of hierarchically clustered promoter regions of highlighted 
genes. Genes with absolute value (log2 FC) > 1 are assigned the most extreme colors. (C) Scatter plots of ATAC-seq promoter log2 FC and in silico pseudo-bulk RNA-seq 
log2 FC with blue and red arrows indicating enrichment in Tfh and TH1 compartment, respectively. (D) Volcano plot of cytokine promoter region accessibility with blue and 
red dots indicating increased accessibility in Tfh and TH1 compartment, respectively, and highlighted gene tracks. (E and F) Enriched motifs in long-lived Tfh (E) or TH1 
memory cells (F) found by HOMER.
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and stem cell–associated sets in treated samples compared with con-
trols (Fig.!7D). These data emphasize the importance of ICOS sig-
nals in maintaining long-lived Tfh identity.
At late time points after LCMV infection, antibody titers are 
maintained by plasma cells present in the bone marrow (66,!67). 
However, up to 1 year after infection, about 20% of the total plasma 
cell compartment is found in the spleen, with an estimated half-life of 
172 days (68,!69). The contribution of long-lived Tfh cells to plasma 
cell maintenance or antibody titers has not been considered due to 
the previous inability to detect Tfh cells at late time points. To assess 
whether late ICOS blockade and subsequent decline of the long-lived 
Tfh cell compartment affect late phase humoral responses, we mea-
sured LCMV-specific antibody titers in the serum of treated and 
control mice at day >60. Here, we observed an almost twofold de-
crease in NP-specific immunoglobulin G (IgG) antibody titers with 
ICOS blockade (Fig.!7E). To determine whether the decline in anti-
body titers correlated with fewer plasma cells in the bone marrow or 
spleen, we measured the number of NP-specific plasma cells by 
ELISpot. Here, we observed that anti-ICOSL treatment correlated 
with a twofold decrease in the number of splenic plasma cells, with 
no impact on the number of bone marrow plasma cells (Fig.!7E). 
Assuming that ICOS blocking is 100% efficient and that circulating 
IgG has a half-life of about 8 days, these data reveal a sizeable and 
ongoing contribution of splenic plasma cells to antibody maintenance 
at this time point (fig. S7C). Because both anti-ICOSL and 2-DG/
rapamycin treatments result in decreased numbers of long-lived Tfh cells, 
we tested whether antibody titers decrease after 2-DG/rapamycin 
treatment. 2-DG/rapamycin did not affect circulating antibody titers 
(fig. S7D). One possible explanation is that the low dose of rapamycin 
used primarily inhibits mTORC1 signaling, whereas ICOS signals 
are additionally mediated by mTORC2 (43). In support of this idea, 
anti-ICOSL treatment decreased the expression of mTORC2 target 
proteins IL-7R and CCR7 on Tfh cells, whereas Tfh cells from 2-DG/
rapamycin and control mice maintained higher levels of these proteins 
(fig. S7E).
To further assess humoral responses, we counted germinal cen-
ters (GCs) at late time points after LCMV infection using immuno-
histochemistry. Although GCs were clearly detected at day 15 after 
infection, their number at day 54 was comparable with the number 
in uninfected mice of a similar age (fig. S7F). We next used an NP 
tetramer to determine whether virus-specific B cells were affected 
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Fig. 7. ICOS signaling maintains Tfh cell identity. (A) Mice infected with LCMV followed by anti-ICOSL treatment at late time points after infection. LCMV-specific CD4+ 
T and B cells analyzed after 12 days of treatment. (B) Cell numbers of GP66-specific long-lived Tfh cells in treated mice using different gating strategies. (C) Scaled, centered 
expression of 20 most significant differentially expressed transcripts in long-lived Tfh cells between control and anti-ICOSL–treated mice. (D) Most significantly down- 
regulated gene signatures with anti-ICOSL–blocking (false discovery rate < 0.2) (3, 17, 20, 29, 30, 36, 43, 91, 92). (E) NP-specific IgG serum titer [far left, optical density (O.D.) 
measured in 1:8100 dilution], numbers of NP-specific GL7+ B cells (left), and NP-specific antibody-secreting cells (ASC) from the spleen (right) and bone marrow (far right). 
Data represent one of N = 2 independent experiments with n = 5 mice per group (B). Data summarize N = 2 independent experiments with n = 9 to 10 mice per group, and 
bars indicate the mean (E). Unpaired two-tailed Student’s t test was performed for (B) and (E) with *P < 0.05 and **P < 0.01.
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immunoglobulin (swIg) memory B cells were unaffected, but there 
was a significant decrease in the number and proportion of GL7+ B 
cells (fig. S7G and Fig.!7E). These cells did not express Fas, a marker 
normally associated with active GC B cells and that, when absent, has 
been reported to preferentially support plasma cell differentiation 
(fig. S7H) (71). GL7+Fas" B cells were also negative for CD38 and 
CD138, distinguishing them from B memory or plasmablasts (fig. 
S7I). In addition, most of these cells were double negative for IgM 
and IgD and expressed both CD73 and CD80, markers associated 
with prior participation in a GC reaction (fig. S7J) (72). Together, 
these data demonstrate an essential role for ICOS signaling in main-
taining the long-lived Tfh compartment and plasma cell survival in 
the spleen.
DISCUSSION
In this study, we determined that the CD4+ memory compartment 
contains an abundant and highly persistent population of long-lived 
Tfh cells with broad recall capacity after secondary challenge. The 
presence of Tfh memory has been controversial. Although cells with 
Tfh cell markers have been identified in the memory phase after in-
fection, it is unclear whether they represent an ongoing immune 
response, whether they are “rested down” Tfh memory cells, or whether 
they are a distinct population of self-renewing Tcm cells with Tfh-like 
characteristics (73). Our data demonstrating the extreme suscepti-
bility of Tfh cells to death during isolation from the tissue shed light 
on the previous difficulty in discriminating these possibilities. Earlier 
studies reporting that Tfh memory cells have a muted phenotype, 
with decreased or absent expression of CXCR5 and PD1, respectively, 
were conducted with monoclonal populations of TCR transgenic cells 
transferred in high numbers that may not accurately reflect the breadth 
in differentiation of a polyclonal repertoire (3,!12,!21). Consistent 
with the idea that T cell differentiation can be partially informed by 
TCR signals, a cell-intrinsic bias for various TCR transgenic strains 
has previously been reported (21). In addition to confirming more 
limited long-lived Tfh differentiation by two distinct TCR transgenic 
strains, we show that treatment with NICD protector rescues poly-
clonal Tfh cells at all time points, preserving their phenotype and 
exposing their metabolic fitness and unexpected longevity. In con-
trast, Tcm cells, generally considered to be self-renewing and multi-
potent, are largely absent at the latest time points after infection. 
Previous studies have suggested the existence of memory cells with 
a hybrid Tfh/Tcm phenotype, namely, dual expression of CXCR5 and 
CCR7 (6,!12,!20). Our data on NICD-susceptible samples confirm a 
population of CXCR5+CCR7+ memory cells that likely represents 
cells on the border of transition from Tfh to Tcm/TH1. However, the 
addition of NICD protector reveals that these transitional cells 
constitute a small minority of the total CD4+ population at memory 
time points. When cells are protected from NICD, CCR7 and CXCR5 
are negatively correlated. In addition, we show that CXCR5 as a marker 
to define the Tfh memory compartment is complicated by the expres-
sion of this protein in non-Tfh subsets. Using scRNA-seq and flow 
cytometry, we demonstrate that long-lived Tfh and Tcm populations 
are more clearly discriminated by Izumo1r/FR4 expression.
We further show that long-lived Tfh cells require ongoing ICOS 
signals and mTOR/glycolysis for their survival. These observations 
suggest that maintenance of long-lived Tfh cells is an active process. 
In the absence of ICOS signaling, long-lived Tfh cells may re-localize 
and acquire TH1 memory cell characteristics, as previously reported 
for Tfh effector cells (74). This idea is consistent with our experiments 
demonstrating the inherent plasticity of long-lived Tfh cells after 
transfer, although under unperturbed conditions, ICOS-mediated 
retention of long-lived Tfh cells in proximity with B cells may limit 
their secondary effector potential. These data are also in line with a 
recent study showing the importance of ICOS signals for the main-
tenance of lung-resident CD4+ T cells induced by tuberculosis infec-
tion (75). Our scRNA-seq data reveal transcriptional similarity between 
long-lived Tfh and Trm cells, both recognized as noncirculating sub-
sets. As both residency and mTOR gene expression signatures are 
reduced in long-lived Tfh cells after ICOS blockade, it will be inter-
esting to determine whether ICOS and mTOR signals are required 
to sustain Trm cells after acute infection.
The constitutive glycolytic phenotype we observed in long-lived 
Tfh cells occurs together with high expression of TCF1 and CD27, 
both associated with self-renewal and plasticity. These data are notably 
in contrast to many studies showing a positive correlation between 
catabolic metabolism and stem-like features. In general, effector T cell 
differentiation is associated with a more glycolytic metabolism, whereas 
memory T cells exhibit a shift toward oxidative metabolism (76). 
Previous studies have shown that inhibition of mTOR signals pro-
motes the generation of both CD4+ and CD8+ memory T cells (77–79). 
mTOR activation was also recently shown to mediate the differen-
tiation of metabolically quiescent, TCF1-positive TH17 cells into 
inflammatory TH1 effectors (50). On the other hand, CD4+ memory 
T cells require Notch-dependent glucose uptake for survival, and 
CD8+ T cells with enforced glycolytic metabolism are still able to 
generate memory T cells with robust recall capacity, albeit with a 
bias toward the CD62Llo Tem phenotype (80,!81). Similarly, human 
CD4+ Tem cells have an increased glycolytic reserve and depend on 
glycolysis to maintain mitochondrial membrane potential, regulating 
both survival and recall potential (82). Together, our findings suggest 
that engagement of a specific metabolic pathway does not universally 
underlie the differentiation of memory T cells and that different types 
of memory T cells may preferentially use metabolic pathways that are 
tuned to a particular immune context (e.g., availability of cytokines, 
nutrients, antigen, etc.).
Last, our data reveal an unexpected role for Tfh cells in supporting 
splenic plasma cells and systemic antibody titers at time points when 
the immune response has supposedly died down. Because of the ap-
parent absence of long-lived Tfh cells without NICD protector, a role 
for Tfh cells was not previously considered. One possibility is that 
persistent antigen fuels the continuous differentiation of memory 
B cells into plasma cells (83). The observation of decreased NP-specific 
GL7+ B cells after ICOS blockade is compatible with this idea, al-
though GL7+ B cells isolated at these late time points did not express 
Fas and therefore have an unusual phenotype. It is possible that 
GL7+Fas" cells received fewer costimulatory signals (e.g., CD40 
cross-linking), which would otherwise induce Fas expression, or 
that these cells are recent GC emigrants, which may later up-regulate 
CD38 and transition into the memory B cell compartment. We also 
did not see a change in NP-specific plasmablast numbers, although 
we cannot exclude effects of technical limitations. In addition, abun-
dant Tfh cells were detected 400+ days after infection, which points 
to either astonishingly long antigen persistence or an alternative 
explanation. Another possibility is that ICOS blocking interferes with 
the structural organization of the spleen and/or plasma cell niche. 
Plasma cell survival depends on the availability of soluble factors, 
such as IL-6, IL-21, and B-cell activating factor (BAFF), all of which 
 at O



















Künzli et al., Sci. Immunol. 5, eaay5552 (2020)     6 March 2020
S C I E N C E  I M M U N O L O G Y  |  R E S E A R C H  A R T I C L E
13 of 16
can be produced by Tfh cells (84). Both CD4+ T cells and BAFF were 
recently identified as key factors supporting the survival of splenic 
plasma cells, but the nature of CD4+-derived signals was not report-
ed (85). One way to discriminate the function of long-lived Tfh cells 
will be to understand where these cells are localized. During the ef-
fector phase, Tfh cells localize to B cell follicles by interacting with 
ICOSL expressed by bystander B cells (86). If long-lived Tfh cells sup-
port the conversion of memory B cells into plasma cells, we would 
expect this colocalization to continue at late time points after infec-
tion. On the other hand, if long-lived Tfh cells directly provide sur-
vival signals to plasma cells, they may be localized in or near the red 
pulp. In this scenario, long-lived Tfh cell interactions with CD11c+ 
ICOSL- expressing antigen presenting cells would be impaired by 
ICOSL blockade, leading to a loss of Tfh cells (87).
The observation that ICOS blocking reduces NP-specific IgG titers 
roughly twofold is unexpected if splenic plasma cells make up only 
20% of the total plasma cell pool, as has been previously estimated 
(67). One possibility is that this original calculation underestimates 
the number of splenic plasma cells at this time point; alternatively, 
antibody output from splenic plasma cells may be higher compared 
with bone marrow cells. With respect to the first possibility, the orig-
inal estimate of 20% is based on the number of plasma cells in the 
mouse femur, under the assumption that all bone marrow compart-
ments have equivalent plasma cell activity. However, a recent study 
in macaques demonstrated that plasma cells preferentially accumulate 
in the femur compared with other bones, suggesting that the current 
conversion factor for mice—based solely on counts from the femur— 
may overestimate the total number of bone marrow splenic cells (88).
In summary, our data establish long-lived Tfh cells as an attractive 
target for vaccination. The question remains, however, as to whether 
these cells can be termed memory cells. This debate assumes a classical 
definition of memory, hinging on questions of antigen availability 
and dependence. Although our experiments demonstrate that a large 
proportion of polyclonal Tfh cells can survive in the absence of anti-
gen, their recovery is highest after transfer into infection-matched 
recipients. Nevertheless, at day 400+ after infection, when residual 
antigen is unlikely to play a major role, Tfh cells make up a substantial 
proportion of the antigen-specific compartment. When identified by 
the absence of CCR7 and CD62L, long-lived Tfh cells can be considered 
a Tem subset. CD4+ Tem cells were recently shown to be generated in 
response to a universal influenza vaccination and to correlate with 
accelerated and improved cellular and humoral secondary responses 
after challenge (89). In contrast, the unanticipated scarcity of Tcm cells 
at late time points that we report here combined with their more 
limited recall potential indicates that vaccines targeting Tcm may not 
offer optimal long-term protection.
MATERIALS AND METHODS
Study design
The aim of this study was to understand the longevity and differen-
tiation potential of distinct CD4+ memory T cell subsets. We used 
the murine LCMV infection model and major histocompatibility 
complex II tetramers to identify polyclonal antigen-specific CD4+ 
memory T cells. Detailed descriptions of experimental parameters 
(sample sizes, number of experimental replicates, and statistical 
analysis) can be found below or in figure legends. Infected mice were 
randomly assigned to treatment versus control groups. Analysis of 
the experimental data was conducted in an unblinded manner.
Mice
Mice were bred and housed under specific pathogen-free conditions 
at the University Hospital of Basel according to the animal protection 
law in Switzerland. For all experiments, male or female sex-matched 
mice that were at least 6 weeks old at the time point of infection 
were used. The following mouse strains were used: C57BL/6 CD45.2, 
C57BL/6 CD45.1, Nur77 green fluorescent protein (GFP), c-myc 
GFP (provided by T. Schroeder, Department of Biosystems Science 
and Engineering, Switzerland), T-bet ZsGreen (provided by J. Zhu, 
National Institutes of Health, USA), P2X7R!/! (provided by F. Grassi, 
Institute for Research in Biomedicine, Switzerland), SMARTA, and NIP 
(S. Crotty, La Jolla Institute for Allergy and Immunology, USA).
NICD protector
Mice were intravenously injected with 25 mg of commercial (BioLegend, 
no. 149802) or 12.5 mg of homemade ARTC2.2-blocking nanobody 
s+16 (NICD protector) 15"min before organ harvest. NICD protector 
was used in every experiment (including adoptive transfers) except 
for when the goal was to compare NICD protector treatment to no 
treatment (Fig."1,"A"and"C, and figs. S1, C to E and G, and S3, I to K).
Statistical analysis
For statistical analysis, the tests that were used are specified in each 
figure legend. In time course experiments, statistical analysis was 
performed for each individual time point. Error bars show SD cen-
tered on the mean unless otherwise indicated. Data were analyzed 
with GraphPad Prism software (version 7 or 8). *P"<"0.05, **P"<"0.01, 




Fig. S1. Tfh cells are susceptible to death during isolation.
Fig. S2. FR4 discriminates long-lived Tfh from transcriptionally distinct Tcm.
Fig. S3. Long-lived Tfh cells are constitutively glycolytic.
Fig. S4. Antigen is not required for the survival of long-lived Tfh cells.
Fig. S5. Tfh cells generate multiple cell fates upon recall.
Fig. S6. Epigenetic regulation of long-lived Tfh cells.
Fig. S7. ICOS signaling maintains Tfh cell identity at late time points.
Fig. S8. Normalization of ATAC-seq data.
Table S1. Raw data file (Excel spreadsheet).
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Mice were infected by intraperitoneal (i.p.) injection with 2x105 focus forming units 
(FFU) of LCMV Armstrong or intravenously (i.v.) with 1x107 colony forming units 
(CFU) ActA deficient Listeria monocytogenes (Lm.ActA). In adoptive transfer studies, 
recipient mice were infected with LCMV Armstrong by i.p. injection with 2x105 on the 
day following cell transfer. LCMV was grown on BHK-21 cells and titrated on 3T3-
cells as described previously (93). 
 
In vivo treatments 
Anti-ICOSL (HK5.3, Bioxcell, #BE0028) treatment was performed by i.p. injection. 
Each m e ecei ed 4 injec i n  f 100 g e e  72 h . 2-Deoxy-D-glucose 
(Sigma, #D8375) was supplied in the drinking water for 14 days at a concentration of 
6mg/ml. Rapamycin or vehicle control (1% DMSO in PBS) was given daily by i.p. 
injec i n f 75 g/kg b d  eigh  f  14 da . F  B dU labelling e e imen , B dU 
was provided in the drinking water at 0.8mg/ml for 12 days.  
 
Mixed bone marrow chimeras and adoptive transfers 
Wild-type (WT) host CD45.1 mice were lethally irradiated with 2 fractionated doses 
f 500 cG  and ec n i ed i h a 1:1 mi e f b ne ma  cell  f m CD45.1 
WT and P2X7R-/- CD45.2 donor mice. The reconstitution ability of T- and B cells was 
assessed at least 6 weeks after reconstitution and before LCMV infection. Adoptive 
transfer experiments with CD4+ SMARTA and NIP cells were performed as 




RNA from sorted cells was isolated with RNAqueousTM-Micro Total RNA Isolation Kit 
(InvitrogenTM) and was reverse transcribed to cDNA using either qScript XLT cDNA 
SuperMix (Quantabio) or iScriptTMcDNA Synthesis Kit (Bio-Rad). Samples were run 
on an Applied Biosystems Viia7 Real-time PCR system. Primers used for the 
indicated genes are listed in the supplementary table. 
  
Isolation of lymphocytes 
Single-cell suspensions of cells were prepared from lymph nodes, spleens, blood, 
liver, and bone marrow. Lymph nodes (inguinal, brachial and axillary) were mashed 
and filtered th o gh a 100 m aine . Spleen  e e ei he  ma hed and fil e ed 
h o gh a 100 m aine  (fo  T cell anal i ) o  dige ed a  37 C fo  1 ho  ing 
Collagenase D and DNase I (for B cell analysis). To isolate bone marrow, femur and 
tibia bones were flushed i h a 25G needle follo ed b  fil a ion h o gh a 100 m 
aine . Li e  e e pe f ed i h PBS and ma hed h o gh a 100 m aine , 
followed by gradient centrifugation in Percoll. Lymphocytes from the blood were 
isolated by gradient centrifugation in Ficoll (LSM MP Biomedicals). Erythrocytes 
were lysed using Ammonium-Chloride-Potassium (ACK) lysis buffer. 
  
Flow cytometry and cell sorting 
Isolation of LCMV-specific CD4+ T cells was performed by staining single-cell 
suspensions for 1 hour at room temperature with IAb:NP309-328 PE or IAb:GP66-77 
APC (provided by NIH tetramer core), followed by enrichment and counting (94). 
Anti-CXCR5 BV421 was added at the time of tetramer staining; for p-S6 detection, 
cells were stained with tetramer for 20 minutes on ice in the presence of 50nM 
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Dasatinib. For transfer of effector or memory cells, tetramer staining was performed 
with 50nM Dasatinib for 1 hour at room temperature. LCMV-specific B cells were 
de ec ed a  pre io l  de cribed, ing a e ramer for NP 340 and a Deco  reagen  
to discriminate PE-specific B cells (70). All other surface staining was performed for 
30min on ice in presence of a viability dye. Transcription factor staining was 
performed by fixation and permeabilization using the eBioscience 
Foxp3/Transcription Factor staining set. To assess phospho-protein levels, cells 
were fixed with BD Phosflow Lyse/Fix Buffer for 10 min at 37°C and permeabilized 
using BD Phosflow Perm/Wash Buffer for 30 min at room temperature. To stain for 
BrdU incorporation, the FITC BrdU Flow kit (BD) was used. 2-NBDG staining 
(Thermo Fi her) a  performed for 10 min a  37 C in 100 M 2-NBDG. To identify 
early apoptotic cells, Annexin V staining (PE, BioLegend, #640907) was performed 
at room temperature for 15min in Annexin V Binding Buffer (BioLegend, #422201). 
Fortessa LSR II and Sorp Aria cytometers (BD Biosciences) were used for flow 
cytometry and cell sorting respectively. Data were analyzed with FlowJo X software 
(TreeStar). 
The following antibodies were used for staining: CD4 (BUV496, GK1.5, BD, 
#564667), CD8a (biotin, 53-6.7, BioLegend, #100704), CD11b (PE-Cy5, M1/70, 
BioLegend, #101222), CD11c (PE-Cy5, N418, BioLegend, #117316), CD27 (BV510, 
LG.3A10, BioLegend, #124229), CD38 (BV421, 90, BD, #562768), CD44 (BUV395, 
IM7, BD, #740215; APC-Cy7, IM7, BioLegend, #103028; PE, IM7, BD, #553134), 
CD45.1 (PE, A20, BioLegend, #110707; FITC, A20, BD, #553775), CD45.2 (FITC, 
104, BD, #553772; APC-eFluor780, 104, eBioscience, #47-0454-82; APC-Fire, 104, 
BioLegend, #109852), CD62L (APC, MEL-14, BD, #553152; BV711, MEL-14, 
BioLegend, #104445), CD69 (FITC, H1.2F3, BD, #553236; PE, H1.2F3, 
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eBioscience, #12-0691-83; APC-Cy7, H1.2F3, BioLegend, #104526; BV785, 
H1.2F3, BioLegend, #104543), CD73 (APC Fire, TY/11.8, BioLegend, #127221), 
CD80 (PE-Cy7, 16-10A1, BioLegend, #104734), CD138(BV421, 281-2, BioLegend, 
#142507; BV711, 281-2, BioLegend, #142519), FAS (PE, 15A7, eBioscience, #12-
0951-83; FITC, 15A7, BD, #554257), PSGL-1 (BV605, 2PH1, BD, #740384, 
BUV395, 2PH1, BD, #740273), CXCR4 (BV711, L276F12, BioLegend, #146517), 
CCR7 (PE, 4B12, BioLegend, #120106; PE-Cy7, 4B12, BioLegend, #120123), 
ICOSL (PE, HK5.3, eBioscience, #12-5985-81), ICOS (PE, 7E.17G9, BioLegend, 
#117406), PD1 (BV785, 29F.1A12, BioLegend, #135225), IgD (BV510, 11-26c.2a, 
BioLegend, #405723), IgM (BV786, R6-60.2, B , #564028), 2 C  ( C, B20.1, 
eBioscience, #11-5812-82, PE, B20.1, eBioscience, #12-5812-82), 8.3 ( C, 
1B3.3, BD, #553663; PE, 1B3.3, BD, #553664), B220 (PE-Cy5, RA3-6B2, 
BioLegend, #103210; BV650, RA3-6B2, BioLegend, #103241; PE-Cy7, RA3-6B2, 
BioLegend, #103222; biotin, RA3-6B2, BD, #553085), CXCR5 (BV421, L138D7, 
BioLegend, #145512), F4/80 (PE-Cy5, BM8, BioLegend, #123112), FR4 (PE-Cy7, 
12A5, BioLegend, #125012, APC-Fire, 12A5, BioLegend, #125013), CD127 (BV711, 
A7R34, BioLegend, #135035), GL7 (Alexa Fluor 647, GL7, BioLegend, #144606; 
Alexa Fluor 48, GL7, BioLegend, #144612), GR-1 (PE-Cy5, RB6-8C5, BioLegend, 
#108410), Ly6C (BV711, HK1.4, BioLegend, #128037; BV510, HK1.4, BioLegend, 
#128033; FITC, AL-21, BD, #553104), I-Ab (biotin, AF6-120.1, BioLegend, 
#116404), NK1.1 (biotin, PK136, BioLegend, #553163), P2X7R (PE, 1F11, 
BioLegend, #148704; PE-Cy7, 1F11, BioLegend, #148707), Bcl6 ( PE-Cy7, K112-
91, BD, #563582; PE, K112-91, BD, #561522; AF488, K112-91, BD, #561524), 
FoxP3 (Alexa Fluor 488, 150D, BioLegend, #320012; PE-Cy7, FJK-16s, 
eBioscience, #25-5773-82), HIF-1a (PE, 241812, R&D Systems, #IC1935P; Alexa 
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Fluor 700, 241812, R&D Systems, #IC1935N), phospho-AKT S473 (Alexa Fluor 647, 
D9E, Cell Signaling Technology, #4075S), phospho-S6 S240/244 (Rabbit mAb, , Cell 
Signaling Technology, #5364S), Goat anti-Rabbit IgG (Alexa Fluor 488, Life 
technologies, #A11034), TCF1 (PE, S33-966. BD, #564217), Zombie Fixable 
Viability Dye (Zombie Red, BioLegend, #423110; Zombie Green, BioLegend, 
#423112). 
 
Enzyme-linked immunosorbent assay 
LCMV-specific NP serum antibody titers were determined as previously described 
(95). Briefly, 96- e  a e  e e c a ed  100  f ec b a  NP a  3 /   
sodium carbonate buffer adjusted to pH 9.6. Plates were blocked with 5% milk in 
PBS-Tween 0.05% before adding the prediluted sera to the plate (3-fold dilutions 
starting with 1:100 dilution of serum). ABTS color reaction was used to detect HRP-
coupled goat anti-mouse IgG antibody (Jackson, 115-035-062). Optical density was 
measured with a Synergy H1 reader (BioTek). 
 
Detection of LCMV NP-specific IgG antibody secreting cells by ELISpot 
LCMV NP-specific antibody secreting cells (ASC) were detected as previously 
described (96). Briefly, 96-well plates were coated with 100ul of recombinant NP at 
3 /   PBS. P a e  e e b c ed  ce  c e ed  bef e add  100  
pre-diluted single-cell suspension from the bone marrow or the spleen (starting at 
2*106 cells/ml and 1*107 cells/ml respectively). Cells were incubated for 5h at 37°C 
before HRP-coupled goat Fcy-specific anti-mouse IgG antibody was added 
(Jackson, 115-035-008). AEC solution (BD Bioscience) was used to detect ASC. 





Spleens were isolated on day 0, 15 or 54 after LCMV infection and frozen in OCT 
matrix (Tissue-Tek). 7 m sections were fixed in ice cold methanol. Sections were 
subsequently stained with 5 g/ml mAb anti- CD4 AF647 (BioLegend, #100426), and 
anti-GL7 AF488 (BioLegend, #144612) and 0.5 g/ml anti-B220 BV421 (Biolegend, 
#103240). Images were acquired on a Nikon Ti2 microscope equipped with a 
photometrics 95B camera, using a 20X objective.  
 
scRNA-seq 
 Sample preparation: 3-10 x 103 LCMV-specific CD4+ memory cells 
(CD4+dump-CD44+GP66+) from either T-bet ZsGreen (1x sample) or wild-type mice 
(2x biological replicates) day 35 and day 37 post infection were provided for library 
preparation using the 10x Chromium platform. Each sample represented cells from 
1-3 mice. Single-cell capture and cDNA and library preparation were performed with 
a Single Cell 3  2 Rea e  K  (10  Ge c ) acc d   a ac e  
instructions. Sequencing was performed on one flow-cell of an Illumina NexSeq 500 
at the Genomics Facility Basel of the ETH Zurich. Paired-end reads were obtained 
and their quality was assessed with the FastQC tool (version 0.11.5). The length of 
the first read was 26 nt, composed of individual cells barcodes of 16 nt, and unique 
molecular identifiers (UMIs) of 10 nt. The length of the second read, composed of the 
transcript sequence, was 58 nt. The samples in the different wells were identified 
using sample barcodes of 8 nt. 
 Sample analysis: Se e c  da a a  ce ed  10X Ge c  
cellranger software version 2.1.0, modified to report only one alignment (randomly) 
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for multi-mapped reads (keep only those mapping up to 10 genomic locations). Raw 
molecule info from cellranger was initially filtered leniently, discarding cells with fewer 
than 100 genes. The resulting UMI matrix was further filtered to keep only cells with 
log library size > 2.8, log number of features > 2.6, % mitochondrial reads <= 6, % 
ribosomal protein reads >= 20. Genes with average counts < .005 were removed. 
N mali a i  a  d e i g he R ackage c a  dec l i  me h d, he e 
cells are pre-clustered, normalized within each cluster, and normalized between 
each cluster. Technical noise within gene expression was modeled using scran, and 
biologically relevant highly variable genes were calculated after separating the 
technical from biological variance, using FDR < 0.05 and biological variance > 0.1. A 
PCA was run on the normalized data using the top 500 most variable genes by 
biological variance, and the PCA was denoised to account for the modelled technical 
variation. Cell  e e cl e ed hie a chicall  i g Wa d s method on the distance 
matrix of the PCA. Default dendrogram cut height using the R package 
dynamicTreeCut resulted in 3 clusters, which also mapped to the highest average 
silhouette width. The cut height for a finer clustering (7) was chosen based on the 
next highest local maximum in a plot of average silhouette width. t-distributed 
stochastic neighbor embedding (tSNE) was executed with a perplexity of 30. GSEA 
between clusters was performed using camera from the limma R package on 
standard gene set categories (MSigDB) as well as sets curated from relevant 
publications (97–99). Subsequent visualization and analysis such as dropout 
imputation were performed using version 2.3.4 of the Seurat R package. Single-cell 
regulatory network inference and clustering (SCENIC) was performed using version 
0.9.7 and the published workflow on the pySCENIC github repository (100). 
Pseudotime analysis was performed with Monocle2 version 2.10.1. Normalized data 
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as above were further filtered to exclude genes found in less than 5% of cells. 
Dimension reduction was performed using DDRTree and differentially expressed 
genes calculated with the differentialGeneTest function based on the hierarchical 
clustering above. The root state of the trajectory was chosen where Tcf7 expression 
was highest.  
 In silico pseudo-bulk data was generated from three biological replicates (one 
without and two with NICD-protector). Biological replicate, percent mitochondrial 
reads and percent ribosomal reads each explained < 0.1 % of variance in the data. 
Counts for each gene were summed by cluster, and data re-normalized using 
Trimmed Mean of M-Values (TMM). Differential expression analysis was performed 
between the most extreme Tfh and TH1 clusters using edgeR and limma. Ingenuity 
Pathway Analysis was performed on the resulting list of differentially expressed 
genes (adj P-value < 0.05). 
 
ATAC-seq 
 Sample preparation: 6.5-7.5 x 103 LCMV-specific Tfh cells (Ly6CloPSGL1lo), 
TH1 cells (Ly6ChiPSGL1hi) were sorted in duplicates from different mice to obtain 
biologically independent samples 32 days post infection. Naïve CD4+ cells (CD44lo 
CD62Lhi) were sorted in duplicates and represent technical replicates. Library 
preparation for sequencing was performed as described previously with an additional 
clean up step to reduce reads mapping to mitochondrial DNA (101). Briefly, sort-
purified cells were lysed and tagmented for 30 min at 37°C. DNA was purified using 
Zymo DNA Clean and Concentrator Kit and amplified for five cycles. Real-time PCR 
was used to determine the number of additional PCR cycles. DNA was cleaned up 
using AMpure XP beads at a 1.2 x ratio twice. Sequencing was performed on an 
Illumina NexSeq 50 machine using 41-bp paired-end run.  
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 Alignment and basic QC: Reads were aligned to the mouse genome (UCSC 
version mm10) with bowtie2 (version 2.3.2) using options "--maxins 2000 --no-
mixed--no-discordant --local --mm". The output was sorted and indexed with 
samtools (version 1.7) and duplicated reads were marked with picard (version 2.9.2). 
The read and alignment quality was evaluated using the qQCReport function of the 
Bioconductor package QuasR (R version 3.5.2; Bioconductor version 3.8). 
 Single sample peak calling: For each group of biological replicates, regions of 
accessible chromation where called with macs2 (version 2.1.1.20160309) using the 
option '-f BAM -g 2652783500 --nomodel --shift -100 --extsize 200 --broad --keep-
dup all --qvalue 0.05'. Since the majority of duplicated reads came from 
mitochondria, the resulting peak lists were cleaned from peaks called in mitochondria 
and additionally ENCODE blacklist regions. All peaks also required a log-fold change 
> 1 and FDR < 0.05. The resulting peak lists, one per population, were merge using 
the function reduce from the GenomicRanges package, requiring at least 250 bases 
gap for separate peak calls and a minimum peak width of 100 bases. This merged 
peak list resulted in 118999 peaks (5.1% genome) across all five populations. The 
Bioconductor package bamsignals was used to generate a counts matrix for the 
merged peak list. 
 Across sample normalization and peak calling: Tfh and TH1 samples differed 
strongly from naïve samples in the enrichment of reads within accessible chromatin 
as compared to genomic background (Supplementary Methods Figure A). One 
possible source of this bias is a differential tagmentation efficiency between samples 
or cell types as previously observed (102). This bias also leads to an artificial 
regulation when comparing ATAC signals of open versus closed promoters 
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(Supplementary Methods Figure B). Here we do not expect a difference in the 
dynamic range between both states across samples/cell types. In order to compare 
log-fold changes across samples we therefore applied quantile normalization to log-
CPM levels of the TMM-scaled peak counts. The resulting peak intensities were 
converted to a Bioconductor ExpressionSet object and all further differential 
accessibility analysis was performed with this object. Specifically, the limma package 
was used for differential accessibility between all pairs of populations using functions 
lmFit and eBayes 
 Differential motif analysis using HOMER: Fasta sequences of TH1 and Tfh 
peaks were extracted using functions from the BSgenome, Biostrings and rtracklayer 
R/Bioconductor packages. These sequences were stratified according to population 
specific peaks (=open in only one population) and common peaks (= open in both) 
based on thresholding the differential accessibility results by logFC > 2 and FDR < 
0.05. Homer (version 4.9) was used to predict known TF motifs (motif database: 
vertebrates/known.motif) within these sequence sets by running the command 
'homer2 known -strand both' with additional setting specifying the specific peaks as 
foreground and the common peaks as background sequence sets. Differential motif 
occurrence 
results were visualized using R. 
 Ingenuity pathway analysis: Ingenuity pathway analysis (Qiagen, version 01-
14) was performed on differentially accessible peak regions (log2 FC > 0.5 and FDR 






 Sample preparation: 0.5-4.0 x 103 GP66-specific Tfh cells (Ly6CloPSGL1lo) 
were sorted in quadruplicates from individual mice to obtain biologically independent 
samples from control and ICOSL treated mice. Total RNA was isolated with the 
PicoPureTM RNA Isolation kit (ThermoFisher, # KIT0202). cDNA and library 
preparation were performed with a SMART-Seq v4 Ultra Low Input RNA Sequencing 
Ki  (Taka a Bi ) acc di g  a fac e  i c i . Se e ci g a  
performed on one flow-cell of an Illumina NexSeq 500 using 38-bp paired-end run. 
 Sample analysis: Single-end RNA-seq reads were mapped to the mouse 
genome assembly, version mm10 (analysis set, downloaded from UCSC 
https://genome.ucsc.edu), with STAR (version 2.7.0c, (103)), with default parameters 
except for reporting only one hit for multi-mappers in the final alignment files 
(outSAMmultNmax=1) and filtering reads without evidence in spliced junction table 
(outFilterType="BySJout").") (103). All subsequent gene expression data analyses 
were done within the R software (R Foundation for Statistical Computing, Vienna, 
Austria). Using Ensembl Genes mRNA coordinates from ensembl version 84 
(https://www.ensembl.org) and the featureCounts function from Rsubread package, 
we quantified gene expression as the number of reads that started within any 
annotated exon of a gene (104). Only genes annotated as "protein_coding" were 
kept for further analysis. Genes that did not show an expression level of at least 0.5 
CPM in each of the 8 samples were filtered out and TMM normalization performed. 
Differential expression analysis was performed with the Bioconductor limma package 
using the function voomWithQualityWeights and applying a cyclic-loess 
normalization. We found this methodology to perform best in dealing with the 
reduced transcriptome complexity in samples with the lowest number of cells used 
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as input. Although no gene was significantly differentially expressed at an FDR 
threshold of 5%, the top genes were consistent with protein expression experiments. 
Gene set enrichment analysis was performed using the cameraPR function from 
limma on standard gene set categories (MSigDB) as well as sets curated from 
relevant publications. 
 
Extracellular metabolic flux analysis 
A Seahorse XFe96 metabolic extracellular flux analyzer was used to 
determine the extracellular acidification rate (ECAR) in mpH/min and the oxygen 
consumption rate (OCR) in pmol/min. In brief, T-cells were sorted in CD4+CD44+ Tfh 
cells (Ly6CloPSGL1lo) or TH1 cells (Ly6ChiPSGL1hi) and seeded (2x105/well at 
memory time point or 2.5 x105/well at effector time point in respective experiments) 
in serum-free unbuffered RPMI 1640 medium (Sigma-Aldrich # R6504) onto Cell-Tak 
(#354240, Coring, NY, USA) coated cell plates. Mito Stress test was performed by 
e en ial addi i n f lig m cin (1 M; Sigma Ald ich 75351), ca b n l c anide-4-
( ifl me h ) hen lh d a ne (FCCP; 2 M; Sigma Ald ich C2920) and 
en ne (1 M; Sigma Ald ich R8875) a  he indica ed ime ints. Metabolic 
parameters were calculated as described previously (105). 
  
Table for qPCR primers 
Gene Forward primer Reverse primer 
Igf1R GCTTCGTTATCCACGACGATG  GAATGGCGGATCTTCACGTAG  
Nav2 CAACCTCAGCACGGATGACATC TTCCTCTCCACCTGTGAGTGCT 
Slc43a1 TTCACATGGTCTGGCCTGG TGTGGTCCAAGGCTAACCC 




Supplementary Figure 1. 
 
Fig. S1. Tfh cells are susceptible to death during isolation. 
(A) Flow cytometry plots of NP-specific splenic CD4+ T cells isolated at day 15 post 
infection, with or without NICD-protector with different gating strategies to identify 
long-lived Tfh cells. (B) Comparison of epitope-specific CD4+ memory cell numbers 

































































































































































































































































































































specific Ly6CloPSGL1hi memory cell numbers (green, gated as in Figure 1D) over 
time with (solid line) or without (dashed line) NICD-protector. (D and E) Flow 
cytometry plots (D) and quantification (E) of splenic LLO-specific Tfh cells isolated 
>30 days post infection with or without NICD-protector after Listeria infection. (F) 
Histogram (left) and MFI (right) of P2X7R in LLO-specific TH1 (red), Ly6CloPSGL1hi 
(green) and long-lived Tfh (blue) cells >30 days post infection. (G) Quantification of 
LLO-specific CD4 memory subsets isolated >30 days post infection with or without 
NICD-protector after Listeria infection. Thin lines represent the mean r s.d. (H) Flow 
cytometry plots (left) and proportions of long-lived Tfh cells (right) in SMARTA and 
NIP memory cells compared to polyclonal memory compartments >30 days post 
infection. Data represent N = 2 (B, D-H) independent experiments with n = 3-5 mice 
or summarize N = 5 independent experiments (H) with n = 4- 9 mice per group (dots 
represent cells from individual mice, and the line represents the mean). Unpaired 
two- ailed S den   e  a  performed for each indi id al ime poin  (C). *P < 





Supplementary Figure 2. 
Fig. S2. FR4 discriminates long-lived Tfh from transcriptionally distinct Tcm. 
(A) Clustering analysis of combined scRNA-seq datasets. Tfh-like clusters in blue (1, 
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clustering. Single cells colored by cluster on x axis with tree height on y axis. (C) 
Imputed expression of selected genes differing between two TH1-like clusters. (D) 
Heatmap showing top 20 genes segregating TH1-like clusters. (E) Log-normalized 
average expression of dysfunction (left) and exhaustion (right) genes. (F) Log-
normalized average expression of published gene sets defining subsets. (G) Flow 
cytometry analysis of total GP66-specific CD4 cells with (right) or without (left) Tfh 
(Ly6CloPSGL1lo) >50 days post infection. (H-I) Representative histograms and 
quantification of CCR7 (H) and proportions of CD69+ cells (I) in Tcm (green) and long-
lived Tfh (blue) cells >100 days post infection in lymph nodes and spleen. (J) Log-
normalized average expression of published Trm signatures. Data represents one of 
N = 2 independent experiments with n = 4 (G) or 5 (H, I) mice. Unpaired two-tailed 





Supplementary Figure 3. 
Fig. S3. Long-lived Tfh cells are constitutively glycolytic. 
(A) Cumulative distribution of scaled, centered mRNA expression by cluster of 
Rictor-regulated genes (mTORC2) (B) Heatmap showing scaled, centered, per-
A B
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cluster expression of leading edge mTORC1-related genes and HIF1-regulated 
genes. (C) Log-normalized average expression of CAMP_PATHWAY and 
BIOCARTA_CSK_PATHWAY gene sets. (D) Secondary analysis of published data 
from Cxcr5- and Cxcr5+ SMARTA CD4+ memory cells showing leading edge Rptor-
regulated genes from Zeng et. al (E) Analysis of published data from day 30 CD4+ 
memory to LCMV: heatmap of expression of Tfh signature genes and cumulative 
distribution of Rptor-regulated genes. (F) Flow cytometry analysis of phospho-S6 
Ser240/244 and MFI in GP66-specific memory TH1 (red) and long-lived Tfh (blue) 
compared to naive CD4 T cells (grey). (G) Flow cytometry analysis of indicated 
markers in CD44+ TH1 memory and long-lived Tfh cells. (H) Cumulative distribution of 
gene set HALLMARK_OXIDATIVE_PHOSPHORYLATION.  
(I-J) Representative histograms and quantification of Annexin V on CD44+ memory 
(I) and CD44+ effector cells (J). (K) Representative histograms and quantification of 
2-NBDG uptake on CD44+ Annexin V- long lived Tfh cells. (L) MFI of FSC-A in GP66-
specific long-lived Tfh cells treated with vehicle or 2-DG/rapamycin. N = 2 
independent experiments with n = 5 (F, G, I-L) mice per group. Line depicts the 
mean and dots cells from individual mice. Unpaired two- ailed S den   e  a  




Supplementary Figure 4. 
Fig. S4. Antigen is not required for the survival of long-lived Tfh cells.  
(A) Representative flow cytometry plot of 2-NBDG uptake (middle) in the different 
LCMV GP66-specific CD4 TH1 memory (red), Tcm (green), and long-lived Tfh (blue). 
2-NBDG uptake versus PD-1 expression in the long-lived Tfh compartment (right). 
(B) Representative flow cytometry plot of 2-NBDG uptake (left) and proportion of 2-
NBDG+ GP66-specific TH1 (red) or Tfh (blue) memory cells (right) 412 days post 
infection. The line represents the mean and each dot represents cells from individual 
mice. Data are representative of N = 1 independent experiments with n = 3 (B) or N 






























































Supplementary Figure 5. 
 
Fig. S5. Tfh cells generate multiple cell fates upon recall. 
 (A) Normalized average scRNA-seq expression of early memory signature. (B) 
Monocle2 analysis showing trajectory in pseudotime (left) and with cluster 




Supplementary Figure 6. 
Fig. S6. Epigenetic regulation of long-lived Tfh cells. 
(A) Venn diagram of all called peaks in Assay for Transposase-Accessible 
Chromatin using sequencing (ATAC-seq) data depicting the overlap of peaks in the 
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(C) Heatmap of hierarchically clustered promoter regions with absolute value 
(log2FC) > 1 in at least one comparison and FDR < 0.1. (D) Heatmap depicting top 
transcriptional network regulators (regulons) on scRNA-seq data found by 
pySCENIC (Single-Cell rEgulatory Network Inference and Clustering) algorithm.  
(E) GSEA analysis of Rptor (left) and Tcf7 (middle) and cAMP (right) regulated 
genes with negative enrichment score indicating enrichment in long-lived Tfh (blue) 
and positive score indicating enrichment in TH1 memory (red). (F) Top 5 pathways 
enriched in long-lived Tfh cells determined by Ingenuity Pathway Analysis in 
combined scRNA-seq data (with and without NICD-protector) comparing Tfh cluster 
to TH1 cluster from 3-cluster version (left) and ATAC-seq peaks mapped to nearest 




Supplementary Figure 7. 
 
Fig. S7. ICOS signaling maintains Tfh cell identity at late time points. 
(A) Flow cytometry analysis (left) and MFI of TCF1 expression in GP66-specific long-
lived Tfh cells comparing PBS (solid line) and anti-ICOSL treated mice (dashed line 
 63 
 
with filled histogram). (B) MFI of FSC-A in GP66-specific long-lived Tfh cells 
comparing PBS vs anti-ICOSL treated mice. The thin line represents the mean and 
each dot represents cells from an individual mouse. (C) Exponential decay model 
showing IgG reduction after 12 days of anti-ICOSL treatment at various starting 
splenic contributions and assuming 100% abrogation of splenic contribution. (D) NP-
specific IgG serum titer at 1:8100 dilution comparing vehicle to 2-DG/rapamycin 
treated mice. (E) Representative histograms and quantification of IL-7R (left) and 
CCR7 (right) expression in gp66-specific long-lived Tfh comparing vehicle, 2-
DG/rapamycin and anti-ICOSL treated mice. (F) Splenic sections stained for B220 
(blue), CD4 (red) and GL7 (green) to identify (left) and quantify (right) germinal 
centers in naïve, day 15 or day 54 post infected mice. (G) Cell numbers of IgD, IgM 
or swIg NP-specific memory B cells comparing PBS and anti-ICOSL treated mice. 
(H) Flow cytometry analysis of NP-specific B cells. (I-J) Flow cytometry analysis of 
NP-specific GL7+ B cells (red) in comparison to CD38+ memory B cells (MBC, black). 
Data is representative of N = 2 independent experiments with n = 4-5 mice per group 
(A-B, D-E, H-J) or summarizes N = 2 independent experiments with n = 9-10 mice 
per group (G). (F) Dots represent individual nonconsecutive sections. The thin line 
represents the mean and each dot represents cells from an individual mouse. 
Unpaired two- ailed S den s  es  as performed i h *P < 0.05, **P < 0.01 and 




Supplementary Methods Figure. 
Fig. S8. Normalization of ATAC-seq data. 
(A) Enrichment of genomic windows in the different ATAC-seq samples. (B) Density 
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A hallmark of the adaptive immune response is the ability of CD4 T cells to 2 
differentiate into a variety of pathogen appropriate and specialized effector subsets.  3 
A long-standing question in CD4 T cell biology is whether the strength of TCR 4 
signals can instruct one Th cell fate over another. The contribution of TCR signal 5 
strength to the development of Th1 and T follicular helper (Tfh) cells has been 6 
particularly difficult to resolve, with conflicting results reported in a variety of models.  7 
Although cumulative TCR signal strength can be modulated by the infection specific 8 
environment, whether or not TCR signal strength plays a dominant role in Th1 9 
versus Tfh cell fate decisions across distinct infectious contexts is not known. Here 10 
we characterized the differentiation of CD4 TCR transgenic T cells responding to a 11 
panel of recombinant wild type or altered peptide ligand lymphocytic choriomeningitis 12 
viruses (LCMV) derived from acute and chronic parental strains.  We found that 13 
while TCR signal strength positively regulates T cell expansion in both infection 14 
settings, it exerts opposite and hierarchical effects on the balance of Th1 and Tfh 15 
cells generated in response to acute versus persistent infection.  The observation 16 
that weakly activated T cells, which comprise up to fifty percent of an endogenous 17 
CD4 T cell response, support the development of Th1 effectors highlights the 18 
possibility that they may resist functional inactivation during chronic infection.  We 19 
anticipate that the panel of variant ligands and recombinant viruses described herein 20 
will be a valuable tool for immunologists investigating a wide range of CD4 T cell 21 
responses.   22 
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• Identification of a wide panel of altered peptide ligands for the LCMV-derived 
GP61 peptide 
 
• Generation of LCMV variant strains to examine the impact of TCR signal 
strength on CD4 T cells responding during acute and chronic viral infection 
 
• The relationship between TCR signal strength and Th1 differentiation shifts 
according to the infection context: TCR signal strength correlates positively 
with Th1 generation during acute infection but negatively during chronic 
infection. 	 	
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Following infection or vaccination, antigen specific T cells undergo clonal 24 
expansion and differentiation into effector cells with specialized functions.  This 25 
process begins with T cell receptor (TCR) recognition of peptide/MHC (pMHC) on 26 
antigen presenting cells (APCs) and is further modulated by cytokines and 27 
costimulatory molecules(1, 2).  Viral infection induces the early bifurcation of CD4 T 28 
cells into Th1 and T follicular helper (Tfh) cells. Th1 cells potentiate CD8 T cell and 29 
macrophage cytotoxicity, whereas Tfh cells support antibody production by providing 30 
survival and proliferation signals to B cells(1, 3).  31 
Although the cumulative strength of interaction between TCR and pMHC has a 32 
clear impact on T cell expansion and fitness, its influence on the acquisition of Th1 33 
and Tfh cell fates is controversial(4-12).  An essential role for TCR signal was 34 
implicated in a study assessing the phenotype of progeny derived from individual, TCR 35 
transgenic (tg) T cells responding during infection(9).  The authors observed that 36 
distinct TCRs induced reproducible and biased patterns of Th1 and Tfh phenotypes.  37 
Although earlier reports suggested that Tfh cell differentiation requires high TCR signal 38 
strength, recent work supports the idea that Tfh cells develop across a wide range of 39 
signal strengths, while increasing TCR signal intensity favors Th1 generation(4-11).  A 40 
central difficulty in reconciling these findings is the use of different TCR tg systems as 41 
well as immunization and infection models that may induce distinct levels of 42 
costimulatory and inflammatory signals known to influence T cell differentiation. 43 
Although existing reports suggest that persistent TCR signaling drives a shift towards 44 
Tfh differentiation during chronic infection, whether this outcome can be modulated by 45 
TCR signal strength has not been examined(13-15). 46 
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The impact of TCR signal strength on CD4 T cell differentiation in vivo has been 47 
historically challenging to address.  The use of MHC-II tetramers to track endogenous 48 
polyclonal T cell responses does not adequately detect low affinity T cells that can 49 
comprise up to fifty percent of an effector response in autoimmune or viral infection 50 
settings(16).  TCR tg models paired with a panel of ligands with varying TCR potency 51 
have been informative, but only a handful of MHC-II restricted systems exist(17, 18).  52 
To bypass these limitations, the generation of novel transgenic/retrogenic TCR strains 53 
or recombinant pathogen strains is required(4, 12, 19, 20).  To our knowledge, this 54 
approach has not yet been used to modify a naturally occurring CD4 T cell epitope of 55 
an infectious agent.  To test the impact of TCR signal strength across different types 56 
of infectious contexts, we generated a series of lympocytic choriomeningitis virus 57 
(LCMV) variants by introducing single amino acid mutations into the GP61 envelope 58 
glycoprotein sequence and expressing them from both acute and chronic parent 59 
strains.  These strains were used to assess the dynamics and differentiation of 60 
SMARTA T cells, a widely used TCR tg mouse line that mirrors the endogenous, 61 
immunodominant CD4 T cell response to LCMV(13).  We observed that depending on 62 
the infection setting, TCR signal strength has opposing effects on the balance between 63 
Th1 and Tfh cell differentiation.  In an acute infection, strong TCR signals preferentially 64 
induce Th1 effectors, whereas weak TCR signals shift the balance toward Tfh 65 
effectors.  In contrast, strong T cell activation during chronic infection induces Tfh cell 66 
differentiation while more weakly activated T cells are biased to differentiate into Th1 67 
cells. Based on these findings we propose a Goldilocks model for the generation of 68 
Th1 effectors during viral infection, where too little or too much TCR signaling skews 69 
the CD4 T cell response toward Tfh differentiation. 70 
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Generation and viral fitness of GP61 LCMV variants 72 
 To generate recombinant LCMV variants, we first screened a panel of altered 73 
peptide ligands (APLs) with single amino acid mutations in the LCMV derived GP61 74 
peptide.  Using the early activation marker CD69 as a proxy for TCR signal strength 75 
we identified 75 APLs for the SMARTA TCR transgenic line (Figure S1A, Figure 1A, 76 
B, Table 1).  We selected twelve of these APLs, covering a wide range of T cell 77 
activation potential, to generate recombinant variant viruses, using site-directed PCR 78 
mutagenesis (21).  Five APL-encoding sequences were successfully introduced into 79 
the genomes of both LCMV Armstrong (Armstrong variants) and Clone-13 (Clone-13 80 
variants), the latter of which contains a mutation in the polymerase gene L that 81 
enhances the replicative capacity of the virus, enabling viral persistence(22, 23). To 82 
exclude a potential impact of differential glycoprotein-mediated viral tropism on CD4 83 
T cell differentiation, we equipped both the Armstrong- and Clone-13-based viruses 84 
with the identical glycoprotein of the WE strain and introduced the epitope mutations 85 
therein (resulting viruses referred to as rLCMV Armstrong and rLCMV Clone-13, 86 
respectively)(24).  Of these viruses, two variants, V71S and V72F (EC50 ~ 0.1 µM and 87 
1µM, respectively) demonstrated comparable viral fitness in vitro and in vivo (Figure 88 
1C, D).  We further performed an out-competition assay with invariant chain knockout 89 
splenocytes to ensure comparable presentation of these APLs by MHC-II (Figure 90 
1E)(25).  Taken together, these data demonstrate the development of a novel tool to 91 
examine the impact of TCR signal strength on SMARTA T cells activated by either 92 
acute or chronic viral infection.   93 
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Figure 1: Generation and viral fitness of GP61 LCMV variants 
(A) Scheme of GP61 wt and APL sequences with mutations highlighted in red 
ordered hierarchically according to TCR signal strength. 
(B) Peptide dose – activation curves of overnight cultured SMARTA cells with 
peptide pulsed splenocytes using the percentage of CD69+ SMARTA cells as a 
readout for activation. EC50 values are ~ 5 nM for GP61 wt, ~ 0.1 µM for V71S and ~ 
1µM for Y72F. 
(C) In vitro growth kinetics depicting the viral load in the culture medium (FFU/ml, 
focus forming units) of GP61 wt or V71S and Y72F variants of Armstrong (left) and 
Clone-13 (right) variant infection on BHK21 cells over time. Data are displayed as 
mean ± SD. 
(D) Early splenic viral load day 3 post infection (p.i.) in Armstrong variants. Bars 
represent the mean and symbols represent individual mice. 
(E) Peptide dose – response curves depicting the out-competition of the GP61 FITC 
signal by unlabeled GP61 wt or variants on B220+ B cells. Data are displayed as 
mean ± SD of 2-3 technical replicates.  
Data represent one of n = 2 independent experiments (B, D-,E) or pooled data from 
n = 2 independent experiments (C). 
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Figure S1: Generation and viral fitness of GP61 LCMV variants 
(A) Peptide dose – activation curves of overnight cultured SMARTA cells with 
peptide pulsed splenocytes using the percentage of CD69+ SMARTA cells as a 
readout for activation. 
Data represent one of n = 2 independent experiments. 
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APL	 EC50	[M]	 	 APL	 EC50	[M]	
GP61wt	 5.2E-09	 	 V71	 W	 5.9E-08	
Y68	 A	 1.3E-06	 	 V71	 P	 2.2E-06	
Y68	 V	 7.2E-08	 	 V71	 M	 1.2E-08	
Y68	 L	 6.5E-06	 	 V71	 C	 2.1E-07	
Y68	 I	 1.3E-07	 	 Y72	 S	 4.2E-05	
Y68	 S	 2.6E-06	 	 Y72	 T	 1.7E-05	
Y68	 T	 4.8E-07	 	 Y72	 E	 2.1E-07	
Y68	 N	 1.6E-07	 	 Y72	 R	 2.1E-06	
Y68	 E	 7.0E-05	 	 Y72	 F	 9.6E-07	
Y68	 Q	 6.7E-06	 	 Y72	 P	 6.3E-08	
Y68	 K	 1.1E-06	 	 Y72	 M	 5.6E-05	
Y68	 R	 1.5E-06	 	 Q73	 L	 8.7E-08	
Y68	 H	 3.1E-07	 	 Q73	 S	 2.5E-05	
Y68	 W	 1.4E-08	 	 Q73	 D	 3.2E-06	
Y68	 P	 1.1E-05	 	 Q73	 E	 3.1E-07	
Y68	 C	 1.0E-06	 	 Q73	 K	 8.3E-06	
Y68	 M	 1.6E-07	 	 Q73	 W	 2.6E-07	
K69	 G	 5.2E-06	 	 Q73	 F	 1.1E-07	
K69	 A	 3.2E-08	 	 Q73	 C	 2.9E-07	
K69	 V	 5.0E-07	 	 F74	 V	 8.7E-07	
K69	 L	 5.5E-07	 	 F74	 I	 1.9E-05	
K69	 S	 1.2E-07	 	 F74	 Y	 1.3E-06	
K69	 T	 8.1E-08	 	 K75	 R	 5.1E-07	
G70	 V	 3.5E-07	 	 S76	 D	 1.0E-06	
G70	 L	 1.2E-07	 	 S76	 E	 5.7E-07	
G70	 I	 3.5E-06	 	 S76	 Q	 5.9E-08	
G70	 K	 5.8E-08	 	 S76	 K	 2.0E-07	
G70	 R	 1.1E-07	 	 S76	 R	 2.2E-06	
G70	 F	 1.4E-05	 	 S76	 W	 7.9E-05	
G70	 Y	 1.7E-07	 	 S76	 F	 4.5E-07	
G70	 M	 6.2E-08	 	 S76	 Y	 5.3E-06	
V71	 G	 9.3E-07	 	 S76	 P	 3.8E-07	
V71	 S	 1.4E-07	 	 S76	 C	 5.9E-08	
V71	 D	 1.4E-06	 	 V77	 G	 1.8E-07	
V71	 N	 8.4E-06	 	 V77	 S	 3.6E-08	
V71	 E	 9.5E-06	 	 V77	 D	 4.8E-07	
V71	 Q	 2.9E-06	 	 V77	 E	 6.5E-07	
V71	 H	 2.2E-08	 	 V77	 P	 4.0E-08	
	
Table 1: APLs with altered potential to activate SMARTA and corresponding 
EC50 values.	
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TCR signal strength positively correlates with Th1 cell differentiation during 94 
LCMV Armstrong variant infection 95 
To assess the impact of TCR signal strength during acute viral infection, 96 
SMARTA T cells were transferred into congenic recipients followed by infection with 97 
rLCMV Armstrong GP61 wt, V71S or Y72F. All LCMV variants were capable of 98 
inducing SMARTA T cell expansion at day 10 post infection (p.i.) and a direct 99 
correlation between TCR signal strength and the number of SMARTA T cells 100 
recovered was observed (Figure 2A).  In contrast, expansion of endogenous LCMV 101 
nucleoprotein (NP)-specific as well as antigen-experienced CD44
+
 T cells was similar 102 
across all three viral strains (Figure 2A). The expansion hierarchy among the viruses 103 
was maintained >30 days after LCMV infection (Figure 2A).  104 
We next examined the phenotype of SMARTA T cells, focusing our analyses 105 
on effector cells due to the impaired generation of Tfh memory by SMARTA T 106 
cells(26).  As the Y72F variant induced very few effector cells, we excluded this strain 107 
from further investigation.  Consistent with earlier reports, strong T cell stimulation 108 
induced a larger proportion of Ly6c
+
 Th1 effectors, whereas the proportion of Tfh 109 
effectors was decreased (Figure 2B-D)(4, 8-10). In contrast, the ratio of Th1 and Tfh 110 
effector cells generated by host NP-specific T cells was consistent across all viral 111 
strains, providing an internal control for the comparable ability of these viruses to 112 
induce endogenous T cell responses (Figure 2D, Figure S2A).  Expression of folate 113 
receptor 4 (FR4), an alternative marker for Tfh cell identification, was additionally used 114 
in combination with PD1 to discriminate the Tfh cell compartment, and demonstrated 115 
a decreased proportion of Tfh cells activatd by strong compared to weak TCR 116 
stimulation (Fig. S2B)(26, 27).  Accordingly, the expression of Bcl6 and T-bet, lineage 117 
defining transcription factors for Tfh and Th1 cells, respectively, revealed a mild but 118 
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significant trend toward increased Tbet and decreased Bcl6 in response to strong 119 
stimulation (Fig. 2E).  Importantly, Bcl6 expression was higher on Tfh compared to 120 
Th1 effectors, with no differences observed between strong and weak stimulation 121 
(Figure 2F, S2C).  These data indicate that TCR signal strength is unlikely to exert a 122 
qualitative impact on these subsets.  Notably, we did not observe any impact of TCR 123 
signal strength on the development of PSGL1hiLy6clo T cells, previously reported to be 124 
a less differentiated population of Th1 effectors (Figure S2D)(26).  In sum, consistent 125 
with earlier reports (references?), TCR signal strength positively correlates with an 126 
increased ratio of Th1 to Tfh effectors during acute LCMV infection.    127 
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Figure 2: TCR signal strength positively correlates with Th1 cell differentiation 
during LCMV Armstrong variant infection 
(A) Number of SMARTA (left), NP309
+
 (middle) and CD44
+
 cells (right) 10 days (top) 
or >30 days (bottom) p.i.  
(B) Histograms (top) and relative MFI (bottom) of indicated phenotypic markers in the 
SMARTA compartment 10 days p.i. 








) subset in the 
SMARTA compartment by flow cytometry 10 days p.i. 
(D) Proportion of Tfh (left), Th1 cells (middle) and the Th1:Tfh ratio (right) of the 
SMARTA compartment 10 days p.i. 
(E) Histograms (left) and relative MFI (right) of Bcl6 and Tbet expression in the 
SMARTA compartment 10 days p.i 
(F) Bcl6 and Tbet MFI in SMARTA Th1 and Tfh subsets. 
Data are pooled from n = 2 independent experiments with 7-9 samples per group. 
Bars represent the mean and symbols represent individual mice. Significance was 
determined by unpaired two-tailed Student’s t-tests. 
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Figure S2: TCR signal strength positively correlates with Th1 cell 
differentiation during LCMV Armstrong variant infection 
(A) Proportion of Tfh (left), Th1 cells (middle) and the Th1:Tfh ratio (right) of the 
NP309+ compartment 10 days p.i. 
(B) Identification and proportion of PD1hi FR4hi Tfh cells in the SMARTA 
compartment by flow cytometry. 
(C) Relative MFI of Bcl6 and Tbet expression in the Ly6Clo Th1 SMARTA 
compartment. 
(D) Identification and proportion of Ly6Clo Th1 (Ly6CloPSGL1hi) in the SMARTA 
compartment by flow cytometry. 
Data are pooled from n = 2 independent experiments with 8-9 samples per group. 
Bars represent the mean and symbols represent individual mice. Significance was 
determined by unpaired two-tailed Student’s t-tests. 
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TCR signal strength positively correlates with Tfh cell differentiation during 128 
LCMV Clone-13 variant infection 129 
In contrast to acute LCMV infection, SMARTA T cells responding to chronic 130 
LCMV preferentially adopt a Tfh effector phenotype(14, 15).  The impact of TCR signal 131 
strength within this context has not been determined, although affinity diversity among 132 
endogenous T cells is reportedly similar between acute and chronic LCMV 133 
infection(28).  To directly assess the impact of TCR signal strength during chronic 134 
infection we transferred SMARTA T cells into congenic recipients followed by infection 135 
with rLCMV Clone-13 expressing either GP61 wt, V71S or Y72F.  As an additional 136 
control we infected mice with rLCMV Armstrong which induced a similar expansion of 137 
SMARTA, NP-specific and CD4+CD44+ T cells as its Clone-13 counterpart (Fig S3A).  138 
Consistent with the results from acute infection, SMARTA T cell numbers at day 7 p.i. 139 
positively correlated with TCR signal strength, while the expansion of NP-specific and 140 
CD4+CD44+ T cells was similar in response to all three Clone-13 variants (Figure 3A).  141 
Importantly, infection with rLCMV Clone-13 Y72F induced approximately 2-fold more 142 
SMARTA T cell effectors compared to acute infection, allowing for a thorough 143 
investigation of T cells responding to this very weak potency variant (Figure 3A, Figure 144 
2A).   145 
With respect to T cell phenotype, strong TCR stimulation during rLCMV Clone-146 
13 GP61 wt infection shifted the balance toward Tfh effector cell differentiation when 147 
compared to strong TCR stimulation in the context of acute infection (Figure S3B-C).  148 
Unexpectedly, and in contrast to the Armstrong variants, weaker TCR signaling during 149 
Clone-13 variant infection resulted in increased proportions of both PSGL1hiLy6chi and 150 
PSGL1hiLy6clo Th1 cells with the weakest variant, Y72F, generating the highest 151 
proportion of Th1 effectors (Figure 3B-D, S3D). The shift toward Th1 effectors in 152 
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response to lower TCR signal strength is unlikely due to differences in antigen load as 153 
all variants sustained high viral titers in the kidneys at day 7 p.i (Figure S3E).  In 154 
addition, although the viral titer of intermediate potency variant V71S was slightly 155 
decreased compared to GP61 wt and Y72F infection, NP-specific CD4 T cells 156 
exhibited a similar ratio of Th1 to Tfh effectors across all three infections (Figure S3F).  157 
Taken together, these reveal that TCR signal strength differentially modulates T cell 158 
fate acquisition according to the infectious context. 159 
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Figure 3: TCR signal strength positively correlates with Tfh cell differentiation 
during LCMV Clone-13 variant infection 
Spleens were harvested 7 days after infection with LCMV Clone-13 variants. 
(A) Number of SMARTA (left), NP309+ (middle) and CD44+ cells (right). 
(B) Histograms (top) and relative MFI (bottom) of indicated phenotypic markers in the 
SMARTA compartment. 
(C) Identification of Th1 (Ly6ChiPSGL1hi) and Tfh (Ly6CloPSGL1lo) subset in the 
SMARTA compartment by flow cytometry. 
(D) Proportion of Tfh (left), Th1 cells (middle) and the Th1:Tfh ratio (right) of the 
SMARTA compartment. 
Data are pooled from n = 2 independent experiments with 7-8 samples per group. 
Bars represent the mean and symbols represent individual mice. Significance was 
determined by one-way analysis of variance (ANOVA) followed by Tukey’s post-test. 
 
(which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. 




Figure S3: TCR signal strength positively correlates with Tfh cell 
differentiation during LCMV Clone-13 variant infection 
Spleens were harvested 7 days after infection with LCMV Clone-13 variants. 
(A) Number of SMARTA (left), NP309+ (middle) and CD44+ cells (right). 
(B) Identification of Th1 (Ly6ChiPSGL1hi) and Tfh (Ly6CloPSGL1lo) subset in the 
SMARTA compartment by flow cytometry. 
(C) Proportion of Tfh (left), Th1 cells (middle) and the Th1:Tfh ratio (right) of the 
SMARTA compartment. 
(D) Identification and proportion of Ly6Clo Th1 (Ly6CloPSGL1hi) in the SMARTA 
compartment by flow cytometry. 
(E) Viral load in kidneys. 
(F) Proportion of Tfh (left), Th1 cells (middle) and the Th1:Tfh ratio (right) of the 
NP309+ compartment. 
Data are pooled from n = 2 independent experiments with 7-8 samples per group 
except for (E) where one representative experiment of n = 2 independent 
experiments is shown with 4 samples per group. Bars represent the mean and 
symbols represent individual mice. Significance was determined by one-way analysis 
of variance (ANOVA) followed by Tukey’s post-test. 
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Increasing TCR signal strength promotes the expression of markers 160 
associated with chronic T cell stimulation 161 
 During Clone-13 infection, T cells start to upregulate inhibitory surface markers 162 
associated with chronic activation, a state often referred to as “exhaustion”(15, 29-31).  163 
To understand if TCR signal strength impacts the expression of these markers we 164 
analyzed SMARTA T cells responding to Clone-13 GP61 wt and variant viruses at day 165 
14.  T cells responding to strong TCR signals expressed the highest levels of both 166 
PD1 and Lag3, two well characterized co-inhibitory receptors (Figure 4A-B) (15, 29).  167 
SMARTA T cells co-expressing both PD1 and Lag3 were most abundant following 168 
Clone-13 GP61 wt infection and decreased in response to Clone-13 variant infection 169 
(Figure 4C-D).  Although the viral load was decreased in Clone-13 variant infections 170 
at this time point, the basal activation of CD4+CD44+ T cells was equivalent across all 171 
three strains and clearly above the recombinant LCMV Armstrong control (Figure S4A-172 
B).  Next, we examined the expression of TOX, a transcription factor involved in the 173 
adaptation of CD8 T cells to chronic infection(32-36).  In response to acute infection, 174 
SMARTA Tfh cells expressed higher levels of TOX compared to Th1 cells, consistent 175 
with an earlier study highlighting the importance of TOX for Tfh cell development 176 
(Figure S4C)(37).  In contrast, TOX expression during rLCMV Clone-13 wt infection 177 
was most highly upregulated by Th1 effectors (Figure S4C). In line with the expression 178 
of PD1 and Lag3, TOX was decreased on SMARTA T cells responding to rLCMV 179 
Clone-13 variant viruses, despite being comparably induced on CD4+CD44+ T cells 180 
(Figure 4E, Figure S4D).  TOX was recently demonstrated to be important for the 181 
survival of stem-like TCF1+ CD8 T cells that accumulate during chronic LCMV(34, 38, 182 
39).  Given the transcriptional similarities of TCF1+ CD8 T cells and Tfh cells, we 183 
wondered if TCF1 would be similarly regulated by TCR signal strength following Clone-184 
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13 variant infection(40). Here we observed that unlike TOX expression, TCF1 is 185 
similarly expressed by T cells responding to all three rLCMV Clone-13 variants (Figure 186 
4F, S4E), indicating that TCF1 expression is likely to be maintained independently of 187 
TCR signals. 188 
 
 
Figure 4: Increased TCR signal strength induces expression of markers 
associated with chronic T cell stimulation 
Spleens were harvested 14 days after infection with LCMV Clone-13 based variants. 
(A) Histograms (left) and relative MFI (right) of PD1 in the total SMARTA 
compartment (left) or SMARTA Th1 and Tfh subsets (right). 
(B) Histograms (left) and relative MFI (right) of Lag3 in the SMARTA compartment. 
(C) Identification of PD1+Lag3+ SMARTA cells by flow cytometry compared to naïve 
CD62L+ CD44- CD4 T cells from an uninfected mouse. 
(D) Quantification of PD1+Lag3+ SMARTA cells in the SMARTA (top) or CD44+ 
(bottom) compartment. 
(E) Histogram (left) and relative MFI (right) of TOX in the SMARTA compartment. 
(F) Histogram (left) and relative MFI (right) of TCF1 in the SMARTA compartment. 
Data are pooled from n = 2 independent experiments with 6-9 samples per group. 
Bars represent the mean and symbols represent individual mice. Significance was 
determined by one-way analysis of variance (ANOVA) followed by Tukey’s post-test. 
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Figure S4: Increased TCR signal strength induces expression of markers 
associated with chronic T cell stimulation 
Spleens were harvested 14 days after infection with LCMV Clone-13 based variants. 
(A) Viral load in kidneys. 
(B) Relative MFI (right) of PD1 and Lag3 in the CD44+ compartment. 
(C) Relative MFI of TOX in SMARTA Th1 and Tfh.  
(D) Relative MFI (right) of TOX in the CD44+ compartment. 
(E) Relative MFI of TCF1 in the SMARTA Th1 and Tfh subsets. 
Data are pooled from n = 2 independent experiments with 6-9 samples per group 
except for (A) where one representative experiment of n = 2 independent 
experiments is shown with 4-5 samples per group. Bars represent the mean and 
symbols represent individual mice. Significance was determined by one-way analysis 
of variance (ANOVA) followed by Tukey’s post-test (B,D) or by paired two-tailed 
Student’s t-tests (C). 
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 The results of this study highlight the differential impact of TCR signal strength 190 
in shaping CD4 T cell fate according to the infection context. By systematically 191 
comparing the differentiation of TCR transgenic T cells responding to variant ligands 192 
in two distinct infection models, we demonstrate that the impact of TCR signal strength 193 
is heavily dependent on the infection specific parameters such as antigen load and 194 
inflammation.  195 
The observation that TCR signal intensity correlates with Th1 generation during 196 
acute infection is consistent with accumulating evidence that higher potency ligands 197 
increase T cell sensitivity to IL-2, which likely drives the survival and expansion of Th1 198 
effectors (4, 8, 41-45).  This is similar to the paradigm described for Th1/Th2 cell 199 
differentiation, where stronger signals induce Th1 cells and weaker signals induce Th2 200 
cells(46).  Nevertheless, at very high antigen doses, T cells revert to Th2 201 
differentiation, potentially due to the susceptibility of Th1 cells to activation induced 202 
cell death (AICD)(47, 48).  AICD of Th1 cells might also contribute to biased Tfh 203 
generation at the higher end of TCR signal strength during Clone-13 infection(49, 50). 204 
 The shift of relatively high affinity CD4 T cells toward a Tfh cell phenotype 205 
during Clone-13 infection is well documented(14, 40, 51).  In addition to antigen 206 
persistence, however, Clone-13 presents an altered inflammatory environment which 207 
contributes to an interferon stimulated gene signature and IL-10 production by 208 
chronically activated CD4 T cells(15, 52).  It is possible that the unique cytokine milieu 209 
present during Clone-13 infection cooperates with strong TCR signals to fine tune T 210 
cell fate.  For example, activation of T cells in the presence of IFNα induces T cell 211 
secretion of IL-10 which is positively regulated by TCR signal strength(53, 54).  While 212 
this may ultimately serve to limit host pathology, it may also prevent the accumulation 213 
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of Th1 effectors.  Consistent with this idea, blocking IFNα or IL-10 during Clone-13 214 
infection rescues the Th1 effector compartment and improves viral control, although 215 
this likely depends on the rate of viral replication(55-57).  Within the same 216 
inflammatory context, weaker TCR signals might induce less T cell derived IL-10 which 217 
has been shown to impair Th1 effector cell differentiation(52). Of particular interest, T 218 
cell production of IL-10 during chronic infection depends on sustained, but ERK-219 
independent TCR signals, suggesting that inflammatory versus suppressive cytokine 220 
secretion may have distinct TCR signaling requirements(52).  Future experiments 221 
should address this by determining whether TCR signal strength contributes to 222 
cytokine production as well as cytokine susceptibility (i.e. induction of cytokine 223 
receptors) of effector cells responding during acute and chronic viral infection. 224 
 Finally, the ability of weakly activated T cells to maintain a higher proportion of 225 
Th1 effectors might ultimately contribute to viral control.  The observation that the 226 
weakest Clone-13 variant, Y72F, elicited significantly more expansion than its 227 
Armstrong counterpart demonstrates that prolonged antigen presentation supports the 228 
accumulation of relatively low affinity T cells.  Importantly, our study only follows the 229 
differentiation of T cells specific for a single epitope, while low affinity T cells are 230 
demonstrated to comprise up to half of the endogenous effector T cell response(58).  231 
Going forward, it will be interesting to determine whether targeting the expansion of 232 
lower affinity T cells with the potential to resist functional inactivation and maintain 233 
proliferative potential will improve control of viral infection.  234 
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Material & Methods 396 
 397 
Viruses 398 
Virus rescue was performed as described previously using the pol-I/pol-II-driven 399 
reverse genetic system for LCMV (21). Single amino acids changes of the GP61-400 
epitope were introduced by site directed mutagenesis of the previously described pI-401 
S-WE-GP rescue plasmid (21). This plasmid encodes the nucleoprotein (NP) of the 402 
LCMV Armstrong strain on cis with the glycoprotein (GP) of LCMV WE. Additionally, 403 
the LCMV Armstrong specific D63K mutation was introduced into the GP61-coding 404 
sequence of the WE-GP gene matching the LCMV Armstrong / Clone-13 amino acid 405 
sequence of the GP61 peptides employed in the T cell activation assay. The resulting 406 
S-rescue plasmids were combined either a plasmid expressing either the Armstrong 407 
or the Clone-13 L segment in order to generate acute and chronic variants 408 
respectively. The presence of the desired mutations in the viral genomes was verified 409 
by sanger sequencing of RT-PCR amplicons generated with the OneStep RT-PCR-kit 410 
(Qiagen) using LCMV WE GP-specific primers (GATTGCGCTTTCCTCTAGATC and 411 
TCAGCGTCTTTTCCAGATAG). Viral RNA was extracted from cell culture 412 
supernatants using the Direct-zol RNA MicroPrep kit (Zymo Research). Virus titer were 413 
determined by immunofocus assay as described on NIH/3T3 cells (59). 414 
 415 
Viral growth kinetics 416 
To determine viral replication capacities, BHK21 cells were seeded 24 hours prior to 417 
infection with a MOI of 0.01. Supernatant was collected at indicated time points and 418 
replaced with fresh culture medium. 419 
 420 
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Mice and Animal experiments 421 
Mice were bred and housed under specific pathogen-free conditions at the University 422 
Hospital of Basel according to the animal protection law in Switzerland. For all 423 
experiments, male or female sex-matched mice were used that were at least 6 weeks 424 
old at the time point of infection. The following mouse strains were used: C57BL/6 425 
CD45.2, SMARTA Ly5.1, CD74-/-. Mice were injected with intraperitoneal injection of 426 
2x105 FFU for Armstrong variants or via intravenous injection of 2x106 FFU for Clone-427 
13 variants.   428 
 429 
NICD-protector  430 
Mice were intravenously (i.v.) injected with 12.5μg homemade ARTC2.2-blocking 431 
nanobody s+16 (NICD-protector) at least 15 minutes prior to organ harvest.  432 
 433 
Adoptive cell transfer 434 
Single-cell suspensions of cells were prepared from lymph nodes by mashing and 435 
filtering through a 100μm strainer. Naïve Smarta cells were enriched using Naïve CD4 436 
T cell isolation kit (StemCell). 1x104 SMARTA Ly5.1 cells were adoptively transferred 437 
into Ly5.2 recipients via intravenous injection as previously described (60).  438 
 439 
Flow Cytometry 440 
Spleens were removed and single-cell suspensions were generated by mashing and 441 
filtering the spleens through a 100μm strainer followed by erythrocytes lysing using 442 
Ammonium-Chloride-Potassium (ACK) lysis buffer. SMARTA and endogenous LCMV-443 
specific CD4 T cells were analyzed using IAb:NP309-328 (PE) or IAb:GP66-77 (APC) 444 
(provided by NIH tetramer core) tetramer. Following staining for 1 hour at room 445 
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temperature in the presence of 50nM Dasatinib, tetramer-binding cells were enriched 446 
using magnetic beads and counted as previously published (60). Surface combined 447 
with viability staining was performed for 30min on ice. For transcription factor staining, 448 
fixation and permeabilization was performed according to the Foxp3/Transcription 449 
Factor staining kit (eBioscience). Samples were analyzed on Fortessa LSR II or Canto 450 
II cytometers (BD Biosciences) followed by data analysis with FlowJo X software 451 
(TreeStar). CD4+ T cells were pre-gated on lymphocytes in FSC/SSC, dump-, live 452 
CD4+ cells and then further gated on CD44+ Tetramer- to assess the CD44+ 453 
compartment, CD44+ CD45.1+ GP66+ for SMARTA and CD44+ NP309+ for NP-specific 454 
cells.  455 
The following antibodies were used: CD4 (BUV496, GK1.5, BD, #564667; APC 456 
eFluor780, GK1.5, eBioscience, #47-0041-82), CD11b (PE-Cy5, M1/70, BioLegend, 457 
#101222), B220 (PE-Cy5, RA3-6B2, BioLegend, #103210, PE-Cy7, RA3-6B2, 458 
BioLegend, #103222), CD11c (PE-Cy5, N418, BioLegend, #117316; AF647, N418, 459 
BioLegend, #117312), CD44 (BUV395, IM7, BD), CD45.1 (FITC, A20, BD, #553775; 460 
APC, A20, eBioscience, #17-0453-82), CD45.2 (APC-Fire, 104, BioLegend, 461 
#109852), CD69 (PE, H1.2F3, eBioscience), CD62L (APC, MEL-14, BD, #553152), 462 
PSGL-1 (BV605, 2PH1, BD, #740384), PD1 (BV785, 29F.1A12, BioLegend, 463 
#135225), Vα2 TCR (PE, B20.1, eBioscience, #12-5812-82; FITC, B20.1, 464 
eBioscience, #11-5812-82), Vβ8.3 TCR (FITC, 1B3.3, BD, #553663), F4/80 (PE-Cy5, 465 
BM8, BioLegend, #123112), I-Ab (PE, AF6-120.1, BD, #553552), FR4 (PE-Cy7, 12A5, 466 
BioLegend, #125012), Ly6C (BV510, HK1.4, BioLegend, #128033), Bcl6 (BV421, 467 
K112-91, BD, #563363), T-bet (BV711, 4B10, BioLegend, #644820), TOX (PE, 468 
TXRX10, eBioscience, #12-6502-82), Lag3 (BV421, C9B7W, BioLegend, #125221), 469 
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TCF1 (AF700, 812145, R&D Systems, #FAB8224N), Zombie Fixable Viability Dye 470 
(Zombie Red, BioLegend, #423110).   471 
 472 
CD69 SMARTA activation assays 473 
Serial dilutions of the GP61-wt peptide or APLs were plated. 5x105 Ly5.2 Splenocytes 474 
and 1x105 Ly5.1 SMARTA cells per well were added to the dilution series, stimulated 475 
overnight at 37°C, and subsequently stained and analyzed at the flow cytometer.  476 
 477 
MHC-II out-competition assays 478 
CD74-/- splenocytes were cultured with a custom made GP61-FITC at a fixed 479 
concentration of 1x10-6 M and various serial dilutions of GP61-wt or APLs for 4 hours 480 
at 37°C. After stimulation, the cells were stained and analyzed at the flow cytometer. 481 
The FITC-labelled GP61 peptide was custom made by Eurogentec. 482 
 483 
Statistical analysis 484 
Geometric mean was used to determine the mean fluorescence intensity (MFI) and 485 
values were normalized to the mean of the control group from each experiment before 486 
data was pooled. Pooled and normalized MFIs are referred to as relative MFI. EC50 487 
values were calculated using a sigmoidal dose-response fit in GraphPad Prism 488 
(version 8). For statistical analysis of one parameter between two groups, unpaired 489 
two-tailed Student’s t-tests were used to determine statistical significance. To compare 490 
one parameter between more than two groups, one-way analysis of variance 491 
(ANOVA) was used followed by Turkey’s post-test for multiple comparisons. P values 492 
are indicated on the graphs. Data was analyzed using GraphPad Prism software 493 
(version 8). 494 
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4.1. Project #1: Long-lived Tfh cells 
 
 
Tfh memory & NAD induced cell death 
 
We and others found that Tfh cells in contrast to other CD4 T cell subsets express high 
levels of the stimulatory, ATP-gated ion channel P2X7R (216, 265, 266). Besides the classical 
pathway via ATP, P2X7R can be activated in an alternative way: NAD can trigger the enzyme 
ARTC2.2 to ADP-ribosylate P2X7R, which leads to the continuous activation of P2X7R and 
ultimately to cell death (266). Cell populations that have previously been reported to be 
susceptible to NICD are splenic CD4 Tregs, and non-SLO resident CD8 T cells and NK T cells 
(267-270). This finding can at least partially be attributed to the isolation techniques of cells 
from different organs. Cell preparation at 37°C but not at 4°C leads to externalization of 
phosphatidylserine due to P2X7R activation (271). The common procedure to isolate CD8 T 
cells from the spleen is to mash the organ through a cell strainer to generate a single cell 
suspension followed by surface or tetramer staining at 4°C. However, most T cell isolation 
techniques from non-SLO tissues rely on a digestion reaction carried out at 37°C. Tissue 
destruction inducing NAD release combined with the incubation temperature during digestion 
facilitates NICD. 
In comparison to CD8 T cells, CD4 T cells are more difficult to stain with tetramer due 
to lower affinity of TCR/pMHC interactions in class II vs class I restricted T cells (272). Thus, 
in order to increase the signal, tetramer staining of CD4 T cells is usually performed at room 
temperature or 37°C for at least 1 hour. This renders splenic CD4 T cells but not splenic CD8 
T cells potentially susceptible to NICD.  We found that in line with the high levels of P2X7R 
expression, splenic Tfh cells are long-lived but compared to other CD4 subsets extremely 
susceptible to NICD during tissue isolation. NICD occurs at memory time points (>30 days 
p.i.) but also at the late effector response (day 15 p.i.). However, since Tfh cells are abundant 
at the late effector time point, some proportion of Tfh cells can still be recovered. In contrast, 
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>30 days p.i. Tfh cells are basically absent and therefore have previously been overlooked. 
Notably, TCR stimulation leads to the downregulation of P2X7R and might provide an 
additional reason why NICD is more pronounced at memory time points due to decreased 
antigen signaling after clearance of the pathogen (266). By inhibiting NICD through 
intravenous administration of NICD-protector 15 minutes prior to sacrificing the mouse we 
were able to increase the recovery of Tfh cells at all time points thereby enabling the study of 
a previously invisible Tfh memory population with increased CXCR5 and PD1 expression. 
NICD previously prevented the characterization of bona fide Tfh memory cells which at least 
partially explains the controversial results from previous studies on Tfh persistence. From an 
evolutionary point of view, the fact that TCR engagement leads to P2X7R down-regulation 
might indicate that NICD in Tfh exists to limit bystander Tfh activation which could obscure the 
antigen-specific humoral response or induce autoimmune diseases (273). 
Interestingly, when looking at TCR transgenic cells specific for the glycoprotein 
(SMARTA) or nucleoprotein (NIP) of LCMV, we saw an impairment in Tfh memory generation 
in both TCR-transgenic but not in the polyclonal compartment from the same mouse. Why 
TCR-transgenic T cells fail to efficiently generate Tfh memory cells but show no defect in 
generating Tfh effectors requires further investigation. We speculate that there is a cell-
intrinsic defect preventing SMARTA and NIP cells from generating Tfh memory cells as 
transfer of high and low numbers of naïve transgenic CD4 T cells, which could potentially skew 
the immune response more to one or another subset, didn’t improve the Tfh memory recovery. 
Additionally, the fact that the polyclonal compartment from the same mouse shows no 
impairment in Tfh memory generation excludes a role of the environment on impairment of 
Tfh memory. In agreement with this, a study has previously shown that TCR transgenic cells 
don’t reflect the full breadth of a polyclonal CD4 T cell response and instead stick to a certain 
differentiation pattern (54). Furthermore, a recent publication indicates that the TCR of Tfh 
and non-Tfh cells clonally diverges and that Tfh cells preferentially react to slightly different 
epitopes than non Tfh cells (57). Therefore, one way to overcome the limitation of Tfh memory 
generation in TCR transgenic systems would be to reverse engineer a TCR by sorting Tfh 
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memory cells from a polyclonal compartment, sequence the TCR and then use the sequenced 
TCR to generate a new transgenic mouse.    
 
Tfh memory survival requirements 
 
Due to the fact that Tfh memory cells have previously been overlooked, very little is 
known about their survival requirements. Quiescent T memory cells have been described to 
mainly rely on OXPHOS for energy production, whereas effector cells additionally engage 
extensive glycolysis to meet their energetic demand (274). Within the memory compartment, 
despite decreased energetic needs Tem cells seem to be more closely related to effector T 
cells than to Tcm in regard to their metabolic state. Surprisingly, we found that Tfh memory 
cells in comparison to Th1 memory cells (also referred to as Tem in viral infection models) rely 
on increased glucose uptake even >400 days after infection, which correlates with increased 
ECAR in metabolic flux analysis and increased mTORc1 activity. Blocking glycolysis/mTOR 
using 2-DG/rapamycin treatment resulted in a decreased Tfh memory survival, while other 
compartments were unaffected. 
This finding opens up several questions: What triggers mTORc1 activity? Is the 
requirement for glucose an adaptation to the nutrient poor or hypoxic environment the cells 
are localized in? What is glucose used for in Tfh memory cells? Glucose can be used in 
several ways, as a source for OXPHOS, fueling the pentose phosphate pathway (PPP) crucial 
for NADPH and nucleotide production, or as a source of acetyl groups used for epigenetic 
modifications. These questions could theoretically be addressed with 13C-glucose tracing 
experiments. However, this assay requires a high number of cells that cannot be reached with 
Tfh memory cells isolated from mice without using an unethical number of mice. Nevertheless, 
recent advances in the Crispr/Cas9 methodology potentially allow for specific deletion of 
certain key enzymes at specific checkpoints in metabolic pathways thereby allowing the 
investigation of resource use in a more precise way (275). The use of Crispr/Cas9 additionally 
allows one to circumvent the limitations of metabolic assays performed in this project which 
are relying on ex vivo studies under unphysiological conditions (e.g. increased oxygen 
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tension) which could induce changes in the metabolic state. Isolation of the cells from organs 
can also impact their metabolic fitness as exemplified by the glucose uptake in Tfh memory 
cells: Tfh memory cells only take up glucose if previously treated with NICD protector (265).  
Additionally, blocking of glycolysis and mTOR using 2-DG and Rapamycin is rather unspecific 
and likely has off target effects. For example, 2-DG can be taken up into the cells but its 
degradation into 2DG-6-phosphate, which is the first step in glycolysis and important to feed 
the PPP, is inhibited by its structure and thereby not only leads to blockade of ATP generation 
but also prevents PPP activity or acetyl-CoA synthesis for epigenetic modifications (276). 
However, specifically targeting the enzyme Pgi which is downstream of Glucose-6-phosphate 
would allow the assessment of the impact of glycolysis on cell survival without affecting the 
PPP activity. Ideally, the Crispr/Cas9 approach should be paired with an imaging technique 
like fluorescent microscopy of whole organs or intravital imaging in order to circumvent tissue 
isolation of the target population. Thereby, the metabolic requirements could be determined 
without any mayor flaw in the experimental setup, all assuming a new TCR transgenic mouse 
becomes available that efficiently generates Tfh memory cells.  
 Another important question that has not been fully addressed in this project is whether 
Tfh memory cells need cognate antigenic stimulation for survival. Long-term T cell survival in 
the absence of cognate antigen has been defined as a hallmark feature of memory T cells 
(277). Adoptive transfer experiments into infection matched or naïve mice paired with the weak 
correlation of PD-1 and Nur77 expression (both readouts for TCR activity) indicate that Tfh 
memory cells are able to survive in the absence of cognate antigen, but do better in its 
presence. Furthermore, TCR signaling could be one (of many) possible triggers of mTORc1. 
However, it’s possible that Nur77 expression can be induced by other stimuli than TCR 
signaling and adoptive transfer experiments are very unphysiological. Therefore, a better 
approach to tackle antigen requirement would be to assess survival upon inducible deletion 
of MHCII on antigen presenting cells or the TCRα/β chain on T cells. This approach would 
allow one to address antigen dependence over a prolonged time period without having to 
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transfer memory T cells thereby circumventing a poor take rate in recipient mice and the 
potential alteration of their survival capacity by the transfer procedure. 
 
Tfh memory function 
 
Our data revealed a surprising role for Tfh memory cells in sustaining the late humoral 
response (> day 50 p.i.) which is at least partially mediated through ICOS-ICOSL interactions. 
When inhibiting ICOS signaling, we found a 50% reduction of LCMV NP-specific IgG antibody 
titers in the serum and a reduction in splenic but not bone marrow derived antibody producing 
cells. One possibility is that at this time point, there is still an ongoing differentiation of GL7+ 
GC or ex-GC B cells into SLPC fueled by persisting antigen consistent with an older 
hypothesis (278). In line with this, we noted a decrease in GL7+ NP-specific B cells upon 
blockade of ICOS-ICOSL signaling. However, the GL7+ cells displayed an unusual GC B cell 
phenotype lacking Fas expression, another hallmark marker for GC B cells, indicating that 
they might have undergone germinal center reaction but recently emigrated. This hypothesis 
is challenged by the fact that we were not able to detect germinal centers 50 days after 
infection by histology, indicating that the ongoing germinal center response had already 
decayed which makes it unlikely that ongoing differentiation at a very low level is responsible 
for 50% of the total NP specific IgG antibodies in the serum. Yet, it remains open whether NP-
specific antibody levels decrease to the same extent when ICOS signaling is blocked at very 
late time points, e.g. 300 days after infection. If a similar observation could be made at day 
300 p.i., this would further decrease the likelihood that ongoing differentiation of B cells into 
plasma cells is occurring since it’s unlikely that antigen from an acute infection would persist 
up to that time point. The observation that germinal centers are absent at day 50 p.i. opens 
up an alternative possibility in which Tfh cells might play a role in maintaining LLPCs in the 
spleen. It was previously reported that the splenic compartment contains LLPCs, however, the 
bone marrow was identified as the major reservoir (roughly 80-90%) (279). Since the splenic 
compartment contributes approximately 50% of the NP-specific IgG titers suggests that either 
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a) splenic LLPC numbers have been previously underestimated or b) splenic LLPCs have a 
higher antibody output. Plasma cell numbers from the bone marrow were traditionally 
estimated based on 59Fe labeling studies which indicated that the femur contains 
approximately 6% of total bone marrow cells (280-282). Subsequently, this value was used as 
a conversion factor to estimate total bone marrow cell numbers based on the cells recovered 
from femurs. Isolation and identification of plasma cells from the bone marrow compartments 
femur, tibia, humerus, rib and sternum revealed no difference in ASC activity and lead to the 
assumption that all compartments have equivalent ASC activity with the caveat that some 
bones were precluded from the analysis due to their small size. In contrast, a more recent 
study in macaques showed that ASC tend to accumulate in femur, tibia and humerus while 
other bone marrow sites like radius, vertebrae or iliac crest show decreased ASC activity 
thereby challenging the current conversion factor used to estimate ASC numbers in mice from 
the femur (283). Unfortunately, technical limitations make it challenging to identify antigen-
specific plasma cells, discriminate SLPCs from LLPCs and quantify their antibody output since 
plasma cells express few surface proteins. However, one could investigate the localization of 
long-lived Tfh cells by histology within the spleen to assess whether Tfh memory cells are in 
close proximity to the red pulp and therefore co-localize with splenic plasma cells previously 
identified in this area (284). 
How can Tfh memory cells facilitate help to antibody secreting cells (ASC) 
mechanistically? Not much is known about the survival requirements of LLPCs, yet certain 
factors like IL-6, IL-21, or B-cell activating factor (BAFF) have been linked to contributing to 
plasma cell maintenance and simultaneously can be produced by the CD4 compartment (285, 
286). Another possibility is that CD4 Tfh cells support plasma cell survival indirectly by 
maintaining the structural organization within the spleen. Consequently, anti-ICOSL treatment 
resulting in impaired Tfh memory survival could lead to the destruction of the structural 




Tfh memory classification & plasticity 
 
 Since the discovery of the two distinct circulating memory subsets Tem and Tcm the 
field has been interested in what the functional differences and relations of these subsets are 
to each other (214). The current dogma states that Tem can instantly produce inflammatory 
cytokines upon reencountering the pathogen but show limited proliferation potential, whereas 
Tcm are thought to represent a less differentiated “stem-like” compartment, having limited 
effector functions but secreting large amounts of IL-2 and maintaining high proliferative 
potential. Since it was controversial whether long-lived Tfh cells exist, it was unclear how these 
cells would fit into the current CD4 memory model. Using scRNA Seq, we identified folate 
receptor 4 (FR4) as a marker to clearly discriminate Tcm from Tfh memory cells. Surprisingly, 
we found that 400 days after infection the Tcm compartment was absent whereas the Tem 
compartment, in our infection model also referred to as Th1 memory, and the Tfh memory 
compartment persisted, thereby challenging the current dogma that Tcm cells represent the 
stem compartment. The data further indicates that the Tcm compartment might not represent 
the best target to generate an efficient vaccine. Tem and Tcm cells have been discriminated 
by the expression of CD62L and CCR7: Tem cells are CCR7-CD62L-, whereas Tcm are 
CCR7+CD62L+ (214). Despite the vast overlap of surface marker and transcription factors 
between Tcm and Tfh memory and their high proliferation potential, Tfh memory cells can be 
considered as Tem by their CCR7 and CD62L expression. However, Tfh cells are stingy 
cytokine producers and therefore miss a hallmark feature of Tem, the immediate ability to 
secrete inflammatory cytokines upon reactivation. Additionally, Tfh cells show an enrichment 
in genes associated with tissue residency, indicating that they might be spleen resident 
thereby differing in their migration pattern from both Tem and Tcm. In summary, this indicates 
that the current CD4 memory model is oversimplified as Tfh memory cells don’t fit in any of 
the currently widely accepted memory subsets Tem, Tcm or Trm. However, out of the three, 
Tfh memory cells might fit best into the SLO Trm compartment also shown to exist in CD8 T 
cells (287). 
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We also identified a TCF1/Wnt pathway signature in Tfh cells associated with stem-
like properties and subsequent transfer experiments revealed full plasticity: only the Tfh 
memory compartment could generate all 3 effector subsets. In contrast, cell fates of Tcm and 
Th1 memory cells were more fixed. These data suggest that Tfh memory cells might serve as 
a stem-like reservoir capable of replenishing other CD4 memory subsets like Tcm and Tem. 
Due to the pluripotent potential, Tfh memory cells could be seen as a less differentiated cell 
type or as the default differentiation pathway of a naive CD4 T cell. However, a recent 
publication indicates that Tfh cell differentiation is not the default pathway, as CD4 cells 
deficient in Bcl6 and Blimp-1 (important for Th1 differentiation) don’t generate Tfh cells (288). 
Why Tfh but not Th1 memory cells maintain plasticity and are able to undergo transcriptional 
reprogramming requires further investigation. However, one major limitation of our approach 
is the unphysiological setting of the transfer experiment, where cells are removed from their 
tissue microenvironment which might lead to a forced adaptation to the conditions in the 
circulation. Further studies will be required to investigate whether Tfh cells can also trans-
differentiate into Tcm or Tem in vivo. Additionally, stronger evidence of Tfh memory flexibility 
could be provided by showing plasticity on single cell level, e.g. with time lapse microscopy or 
intravital imaging of transcription factor reporter mice.  
 
Tfh memory as a vaccine target 
 
 To date, vaccine approaches inducing a potent Tfh response scarcely exist. However, 
based on our data, Tfh memory cells provide an attractive vaccine target because of a) their 
important role in shaping and potentiating the humoral response and b) their developmental 
plasticity which potentially allows trans-differentiation into Th1 cells thereby supporting the cell 
mediated response. Work by the Linterman lab has shown that stimulating human germinal 
center responses by using an adjuvant that acts on TLR-4 signaling called “GLA-SE” can 
increase long-lived antibody production (while maintaining the BCR mutation frequency) 
specific to Malaria and correlates with an increased proportion of circulating Tfh cells (289). 
Circulating Tfh cells are a proxy for the size of germinal center reactions in SLOs and have 
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been shown to be transcriptionally and clonally similar to GC Tfh cells in this particular infection 
model (289). Mechanistically, further investigations are required to understand how GLA-SE 
potentiates germinal center reactions, but it is likely indirectly by creating a different 
environment as TLR4 stimulation on naïve CD4 T cells was found to be irrelevant for T helper 
differentiation (290) . The Tfh memory response can likely be further potentiated by combining 
the adjuvant GLA-SE to the ideal epitope that preferentially induces the differentiation of naïve 
CD4 T cells into Tfh cells (and B cell epitopes against which the antibodies should be formed) 
(Figure 4). A recent study revealed that there is little TCR sequence overlap between Tfh and 
non-Tfh cells (57). Surprisingly, there was also a very small overlap between Tfh and non-Tfh 
cells in terms of binding capacity of different peptides from Influenza hemagglutinin (HA) (57). 
Therefore, the pMHCII/TCR interaction between APCs and T cells is likely impacting the 
differentiation of naïve CD4 T cells, nudging them to become a Tfh or a non-Tfh cell. Identifying 
the epitope generating the strongest skew towards Tfh would therefore help to maximize the 
Tfh pool. 
 In which scenarios could targeting Tfh cells be beneficial over classical vaccine 
approaches? In the case of influenza, we predict the dominant virus strain of the upcoming 
season and generate a vaccine based on the prediction. We have to undergo this yearly 
routine because influenza viruses are highly mutative and the antibody response is directed 
against non-conserved regions that fail to facilitate cross-protection to upcoming strains. In 
contrast, CD4 T cells can react to conserved epitopes and therefore might enable a more 
flexible humoral response facilitating universal influenza protection (291). Therefore, Tfh 
memory could be beneficial in a scenario where viruses are slightly mutated from the parent 
strain.  Another example might be Tuberculosis (Tb): CD4 T cells, especially Th1 cells that 
secrete IFN-γ are crucial for control as mice and human with a genetic deficiency are unable 
to control Tb (292-294). Recently, the vaccine candidate MVA85A targeting the CD4 response 
was developed and tested in humans. Unfortunately, despite stimulating a potent Th1 
response, the results were disappointing, showing no statistical improvement in protection 
compared to the low efficacy BCG vaccine (295). A potential explanation for the lack of 
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protection is that the vaccine-induced Th1 cells were found to efficiently produce IFN-γ but are 
short lived and therefore decrease in numbers over time (296). However, in mice a Tfh-like 
population can be found upon Tb infection in the lung (296). Since we observed that Tfh 
memory cells retain plasticity, generating a vaccine that induces a more balanced response 
might provide a pool of “stem-like” Tfh cells that are able to replenish the Th1 effector pool 
and thereby contribute to protection.  
 
Figure 4: Schematic to induce a potent Tfh response. To maximize the Tfh response, one could combine the 
adjuvant GLA-SE which facilitates a beneficial environment for GC responses, with an antigen preferentially 
stimulating Tfh differentiation. The resulting Tfh pool could potentially sustain high levels of antigen-specific 
antibodies while still maintaining the potential to generate inflammatory Th1 effectors to stimulate the cell-mediated 




4.2. Project #2: GP61 variants 
 
A novel tool to study weakly stimulated CD4 T cells 
 
 Due to technical limitations, the impact of TCR signal strength on CD4 T cell 
differentiation has been difficult to study. One major limitation is that tetramer staining for CD4 
T cells mostly captures T cells bearing high affinity receptors. However, weakly stimulated T 
cells that cannot be stained with tetramer but produce cytokines upon peptide stimulation can 
make up a high proportion of responding cells (56). Therefore, to study TCR signal strength 
researchers have mainly relied on TCR transgenic systems combined with altered peptide 
ligands (APL) to model different levels of stimulation through the TCR (41, 47). However, in 
contrast to CD8 T cells, only few APL systems are available for the CD4 compartment, and 
none have been incorporated into viral infection models. The disadvantage of our model is 
that mutating the glycoprotein of the virus comes at a cost of decreased viral 
fitness/persistence within 2 weeks. Combined with the impaired Tfh memory generation in 
SMARTA cells, it might not be possible to adequately study late T cell exhaustion in this setup 
(265). However, the observed effect on the early exhaustion phenotype cannot be explained 
solely by the lack of viral fitness, as the antigen experienced CD44+ compartment showed 
similar levels of chronically activated PD1+ Lag3+ double-positive T cells in all Clone-13 
strains, indicating that this tool is suitable to study early processes inducing T cell exhaustion 
in the CD4 compartment. Furthermore, it can be used to study various other immunological 
contexts, e.g. how TCR signal strength impacts tissue resident memory generation, recall 
responses, Treg differentiation or tumor-restricted effectors. Therefore, this tool fills an 
important research gap and is a contribution to the field of CD4 T cell immunology. 
 
TCR signal strength exerts opposite effects on CD4 T cells  
 
 The impact of TCR signal strength on the CD4 response in the acute Armstrong 
variants confirms what has previously been shown in bacterial infection models: Th1 induction 
positively correlated with TCR affinity at the expense of Tfh generation (41, 54). In contrast, 
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peptide and sheep red blood cell immunization demonstrated a requirement for high affinity 
antigen to efficiently generate Tfh cells (48, 50). However, antigen presentation is likely not 
sustained in these models, and additional factors like different infection-induced inflammatory 
environments, antigen localization or using a polyclonal vs monoclonal approach might explain 
the opposing results. 
The expansion of SMARTA T cells correlated with the TCR signal strength in both 
Armstrong and Clone-13 variants which is in line with previous reports (41). However, 
prolonged TCR signaling in Clone-13 variants can at least partially compensate the expansion 
deficit of cells receiving weak TCR signal in the acute setting as exemplified by the Y72F 
variant. The increase in recovered SMARTA cells is roughly two-fold, with the caveat that the 
mice were harvested at slightly different time points. In contrast, the GP61 wt Armstrong 
variant yielded approximately four-fold more SMARTA cells than its Clone-13 counterpart. 
These observations suggest that continuous TCR signal can have different effects on the 
clonal expansion depending on whether the TCR signal is weak or strong. 
In terms of CD4 differentiation in Clone-13 variants, we observed the opposite effect 
of the acute setting: TCR signal strength positively correlated with Tfh induction at the expense 
of Th1 cells. How can the opposite effect be explained? One possibility is that prolonged 
antigen presentation limits the Th1 response a) by increased susceptibility of Th1 cells to 
activation induced cell death and/or b) increased susceptibility to T cell exhaustion suggested 
by the elevated expression of the exhaustion regulator TOX in the Th1 compartment in our 
data (297). Why strongly stimulated Th1 cells appear to be more susceptible to TOX 
upregulation requires further investigation. One possibility is that the different localization of 
Th1 and Tfh cells within the spleen plays a role. Tfh cells might sit in a more “protected” 
environment after reaching the B cell follicle. In contrast, Th1 cells situated in the red pulp, 
which functions as an antigen filter from the blood, might be exposed to higher levels of 
antigen. Due to the inability to quantify antigen levels in vivo, this hypothesis cannot be 
addressed adequately. Notably, weakly stimulated Th1 cells showed decreased acquisition of 
chronic activation markers, suggesting that these cells might be more resistant to exhaustion. 
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Another possibility is that the altered inflammatory environment in Clone-13 infection 
compared to Armstrong infection contributes to the opposing effects of TCR signal strength. 
It has previously been shown that TCR signal strength positively correlates with IL-10 
induction in T cells in the presence of IFNα and therefore might limit Th1 differentiation to 
ultimately protect the host from an excessive inflammatory response (298-300). It will be 
important to assess how TCR signal strength in the distinct infection contexts influences 
cytokine production as well as expression of cytokine receptors. 
In summary, our data are in favor of a goldilocks model, where the right amount of 
cumulative TCR signal favors a Th1 skewed response. This also indicates that TCR signal 
strength exerts different effects on CD4 differentiation bias based on the immunological 
context. From an evolutionary point of view, the limitation of the Th1 response might be 
beneficial to prevent excessive inflammation and thereby limit immunopathology. It remains 
open how weakly stimulated T cells can be specifically targeted for robust expansion and 
whether these cells are beneficial in the treatment of chronic diseases like HIV or cancer due 
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